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1. ABSTRACT  
Background: Both neurophysiological effects and the clinical outcome of electroconvulsive 
therapy (ECT) are dependent on stimulus dose and placement of the stimulus. The stimulus 
gan be directed over both temples of the head (BT), over the right side of the head (RUL) or 
over the frontal (BF) areas of the head. To find more specific solutions concerning the 
interactions between the technical factors of ECT and the neurophysiological effects and 
clinical outcome is perhaps the most important challenge for present ECT research. The 
efficacy of ECT in major depression has been linked to the accentuation of post-convulsive 
frontal EEG slow-wave activity (delta range) induced by different combinations of stimulus 
placements and stimulus doses. Although the significance of seizure duration as such seems 
at present to play a minor role in the mechanism of action for ECT, an inverse relationship 
between seizure duration and the minimal dose that elicits an adequate seizure, i.e. the 
seizure threshold (ST), has been replicated using RUL and BT stimulus placements. That 
inverse relationship can indicate the estimated ST level reflects at least partly those neural 
processes that determine seizure duration. In clinical practice, the stimulus dose for ECT can 
base on the dose titration method (DTM) on which the estimated ST level is based or on 
methods of a predetermined dose, e.g., the age-method (AM), the half age method (HAM) or 
the fixed high dose method (FHDM). The age-based methods assume a clear relationship 
between the age of the patients and the ST level. There is an on-going debate concerning 
which of these methods should be used. In addition, optimal stimulus doses in each of the 
stimulus placement has been a focus of recent ECT research. Unfortunately, most of the 
recent efficacy studies on ECT have excluded many groups of patients treated with ECT in 
clinical practice. The generality of those studies is therefore clearly limited. 
 
Purpose and Methods: All study patients were hospitalized because of depression. The first 
aim was to investigate any ECT-induced changes, both RUL and BF, in frontal slow-wave 
activity (in the 0.5-3 Hz, delta range, and the 3-7 Hz, theta range) and their relation to clinical 
outcome using a whole-scalp magnetoencephalography (MEG). This method had not been 
previously used for this purpose. Second, this study examined the relationship between 
seizure duration and ST level as estimated by DTM in RUL ECT and made preliminary 
observations for BF ECT. Third, we compared the relationship between DTM, and AM and 
HAM separately for RUL and BF ECT and the relationship between DTM and FHDM also 
for RUL ECT. FHDM has not been used in the clinical practice of BF ECT. This study 
aimed to give guidelines for ECT dosing in the clinical practice of RUL and BF ECT. Fourth, 
this study compared the short-term clinical outcomes between high-dose RUL ECT, 
moderate-dose RUL ECT and low-dose BF ECT. Fifth, the study compared the outcome of 
RUL ECT for patients with pure major depressive episodes, and depressive patients with a 
variety of comorbid conditions or with low severity of the major depressive episodes. The 
latter group of patients has been excluded in most of the recent efficacy studies.  
 
Results: The theta range of the MEG slow-wave activity increased in the right frontal and 
occipital regions during the course of ECT treatment. After four treatments, the increase of 
the theta MEG activity in the left frontal cortex correlated with the efficacy of the ECT 
treatment. Moreover, the change of the ratio of left and right frontal MEG theta activity to the 
occipital theta activity correlated positively with the therapeutic effect. The MEG study 
found no relationship between clinical outcome and delta activity. In RUL ECT, the Study II 
found an inverse relationship between seizure duration and initial ST level. This relationship 
was not found in BF ECT. The ECT dosing methods based on the predetermined dose would 
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have led to give patients with the lowest seizure thresholds in the RUL ECT group very high 
stimulus doses, up to 12 (AM) or 15 (FHDM) times the individual ST. In contrast, the RUL 
ECT patients with the highest ST levels would have received low stimulus doses down to 1.5 
times (HAM method) the initial ST. In the BF ECT group the AM based dose would have 
been similarly dependent on the initial ST level. Patients treated with low-dose BF ECT 
needed more treatments than patients treated with high-dose RUL ECT treatment, i.e. twelve 
vs. seven treatments (Study IV). The heterogeneous depression group responded in a less 
efficient manner (8% vs. 63%) to RUL ECT, and more often had simultaneous worsening in 
the global cognitive functioning than the homogeneous depression group (Study V).  
 
Conclusions: The findings suggest that an efficient ECT treatment regardless of electrode 
placement and stimulus intensity increases MEG theta activity in the frontal cortex. In BF 
ECT, the lack of an inverse relationship between seizure duration and initial ST level may 
indicate that the lowest level in the BF ECT schedule was overestimated. If this really is the 
case, the initial BF ST level would be essentially lower than the previous study conducted 
has estimated. The use of the DTM is recommended in RUL and BF ECT treatments, 
because it is the only method which allows for the individual selection of ECT stimulus doses 
relative to the ST. High-dose RUL ECT seems to have a faster antidepressant effect than low-
dose BF ECT. The ECT effectiveness of RUL ECT treatment was lower in real-life 
heterogeneous patient groups than in homogeneous patient samples used in experimental 
efficacy trials.  
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2. REVIEW OF LITERATURE 
2.1. Depression  
Depression may be considered as a normal human emotion, a symptom of a somatic illness, a 
neuropsychiatric illness or one of the main symptoms of mood disorders. Depression often 
recurs (Angst et al., 1996), it is associated with an increased risk of suicide (Harris and 
Barraclough, 1997), and causes much disability (Wells et al., 1989). The risk of suicide in 
follow-up studies of affective disorder has decreased compared to that reported in previous 
reviews (O’Leary et al., 2001). The availability of ECT and antidepressants (ADs) may have 
contributed to this decrease, but it cannot be assumed that ECT can be prescribed for all 
patients. Depressive illness has been the fourth leading global cause of disability-adjusted life 
years (DALYs) in 1990 and it has been predicted it will be the second leading cause of 
DALYs in 2020 (Murray and Lopez, 1997).  
 
2.1.1. Clinical evaluation 
Different criteria for mood disorders have been used over the last decades. The criteria 
according to Feighner et al. (1972), and the Research Diagnostic Criteria (RDC) (Spitzer et 
al., 1978) have included criteria for both primary and secondary depression. Secondary major 
depression occurs in a person who has a preexisting non-affective psychiatric disorder 
(which may or may not still be present), or a serious or life-threatening medical illness, which 
precedes and parallels the symptoms of depression contrary to primary depression. In 
Finland, the criteria according to the International Classification of Diseases (ICD, version 
10, World Health Organization, 1992) are officially used for mood disorder diagnostic. On 
the other hand, depression studies have widely used the criteria for mood disorders of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) [American Psychiatric 
Association (APA)]. The latest version (DSM-IV) (APA, 1994) has been used in the studies 
which make up this thesis.  
 
DSM-IV defines a mood disorder as a clinically significant behavioral or psychological 
syndrome or pattern that occurs in an individual and that is associated with present distress 
(e.g., a painful symptom) or disability (i.e., impairment in one or more important area of 
functioning) or with a significantly increased risk of suffering death, pain, disability, or an 
important loss of freedom. 
 
The DSM-IV mood disorders are as follows: 1) mood disorder due to a general medical 
condition, 2) substance induced mood disorder, 3) bipolar I disorder, 4) bipolar II disorder, 
5) schizoaffective disorder, 6) cyclothymic disorder, 7) major depressive disorder, 8) 
dysthymic disorder, 9) adjustment disorder with a depressed mood and 10) depressive 
disorder not otherwise specified. The term major depression indicates that the depressive 
disorder is severe.  
 
Diagnoses for major depressive disorders and for bipolar I disorders include a major 
depressive episode. A major depressive episode has a duration of at least two weeks, and it 
represents a change from previous functioning. The major depressive episode includes at 
least five of the following nine symptoms: either 1) a depressed mood or 2) markedly 
diminished interest plus associated symptoms 3) significant weight loss or weight gain when 
not dieting 4) insomnia or hypersomnia 5) psychomotor agitation or retardation 6) fatigue or 
loss of energy 7) feelings of worthlessness or excessive guilt 8) diminished ability to think or 
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concentrate, or indecisiveness and 9) suicidality. The nine symptoms, occurring nearly every 
day during the episode, are the A criteria for a DSM-IV major depressive episode. The 
criteria for a major depressive episode are somewhat different according to the ICD 10 
criteria, e.g. the most typical symptoms include in addition to a depressed mood, and loss of 
interest and enjoyment also reduced energy leading to increased fatiguability and diminished 
activity.  
 
A major depressive episode may occur with melancholic (endogenous), atypical, catatonic, or 
psychotic features. The DSM-IV criteria for major depressive episode with melancholia are 
symptoms no. 1 or 2 and 3 of no. 3-8: 1) loss of pleasure in all or almost all activities, 2) lack 
of reactivity to usually pleasurable stimuli, 3) depression regularly worse in the morning, 4) 
early morning awakening, 5) marked psychomotor retardation or agitation, 6) significant 
anorexia or weight loss, 7) excessive or inappropriate guilt, 8) a distinct quality of the 
depressed mood. The psychotic features found in a major depressive episode according to 
DSM-IV includes delusions or hallucinations and according to ICD-10 delusions, 
hallucinations, or depressive stupor. The clinically different subtypes may be also 
biologically different. It has been suggested that especially psychotic depression may be a 
distinguishable nosological entity that warrants separate treatment algorithms (Petrides et al., 
2001). Estimates for the frequency of occurrence of psychotic depression range from 14% in 
a community sample (Johnsson et al., 1991) up to 54% in clinical practice, particularly in 
treatment-resistant depressed patients (Dubosky and Thomas, 1992). Relapse rates are higher 
and occur earlier in psychotic depressed patients than in nonpsychotic depressed patient. 
Regarding neurophysiological aspects, psychotic depression has been found to occur more 
often among abnormal EEG (62%) than normal EEG (39%) patients (Malaspina et al., 1994). 
 
A major depressive episode can be categorised as severe based on depressive symptoms, on 
scores on a depression rating scale, e.g. Hamilton Rating Scale for Depression (HDRS, 
Hamilton, 1967), and Montgomery and Åsberg Depression Rating Scale (MADRS, 
Montgomery and Åsberg, 1979), on a need for hospitalisation, on depressive subtypes, on a 
functional capacity, on the level of suicidality and on the impact that the depression has on 
the patient (Sonawalla and Fava, 2001). 
 
As many as 30% to 40% of patients with major depressive disorder are unresponsive to AD 
medication (Fava, 2000; Kornstein and Schneider, 2001). At present, there are no commonly 
accepted standards for defining medication resistance. Guscott and Grof (1991) emphasize 
that the problem of treatment-refractory depression has to do primarily with the diagnostic-
treatment process than with patient variables. The questions which should be considered are 
as follows: 1) Is the diagnosis correct? 2) Has the patient received adequate treatment? 3) 
Was a rational stepped-care approach used? 4) How was outcome measured? 5) Is there a 
coexisting medical or psychiatric disorder that is interferring with response to treatment? and 
6) Are there factors in the clinical setting that are interfering with treatment?  
 
The clinical characteristics of depression is further influenced by several biological, 
psychological and social factors, and by the presence of comorbid psychiatric or medical 
illnesses (Weissman et al., 1996; Parker and Kalucy, 1999; Roulloin, 1999).  
 
Recent studies have found that depression is also a risk factor for somatic illnessess such as 
coronary heart disease (Ferketich et al. 2000) and for cardiac mortality (Seiner and Mallya, 
1999). This mortality may be decreased by appropriate treatment of depression (Seiner and 
  12 
Mallya, 1999). Regarding an increased risk for sudden death, high levels of QT variability 
occurs on the electrocardiograms (ECGs) of the patients with an elevated risk for sudden 
death. The increased QT variability has also been found in depressed patients (Yeragani et 
al., 2000).  
 
2.1.2. Epidemiology 
Recent studies have found one-year prevalence rates for a major depressive episode to range 
from 10.1% to 4.5% (Table 1). 
 
Table 1. One-year prevalence rates for a major depressive episode 
     
Reference Total prevalence (%) Females (%) Males (%) Total prevalence 
(%) 
    with clinical 
significance criteria 
Regier et al., 1984 5.8   4.5 
Kessler et al., 1994  10.1   6.4 
Lindeman et al., 2000 9.3 10.9 7.2  
Ayuso-Mateos et al., 2001 6.7 8.0 4.9  
Kringlen et al., 2001 7.3 9.7 4.1  
Pirkola et al., 2002 5.0 7.0 4.0  
Narrow et al., 2002    4.5 
 
Prevalence rates were found to be lower if they were based on the clinical significance of 
depressive disorders (Narrow et al., 2002). This may be important for estimating the needs 
for different treatment. 
 
2.1.3. Etiology 
The causes of mood disorders are unknown (see Kaplan and Saddock, 1998). The causative 
factors can be artificially divided into biological, genetic, and psychosocial, but this division 
is artificial because the three realms most likely interact with each other. 
The monoamine hypothesis, which was first proposed in 1965, holds that monoamines such 
as norepinephrine and serotonin are deficient in depression and that the action of 
antidepressants depends on increasing synaptic availability of these monoamines 
(Schildkraut, 1965). Although the data are not yet conclusive, amino acid neurotransmitters 
[particularly γ-aminobutyric acid (GABA)] and neuroactive peptides (particularly 
vasopressin and the endogenous opiates) have been implicated in the pathophysiology of 
mood disorders (see Kaplan and Saddock,1998). Major depression is a familial disorder, and 
its familiality mostly or entirely results from genetic influences (Sullivan et al., 2000). 
Environmental influences specific to an individual are also etiologically significant (Sullivan 
et al., 2000; Kendler et al., 2001) 
 
2.1.4. Functional Neuroanatomy 
Functional abnormalities in the frontal, subcortical, and limbic structures are associated with 
mood disorders (Mayberg, 1997; Soares and Mann, 1997). The frontal lobes make up 
approximately one-third of the total cortical area of the brain and mediate critical social 
functions such as planning, regulation of behaviour, and drive. Furthermore, there is specific 
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neuropsychological and neurobehavioral evidence for significant prefrontal cortical 
dysfunction in depression (Sweeney et al., 1998; Merriam et al., 1999). Dysfunction of the 
prefrontal cortex, particularly with respect to its role in modulating limbic activity, may 
produce many of the symptoms seen in clinical depression (George et al., 1994). Mayberg 
(1997) has suggested that dorsal neocortical decreases and ventral paralimbic increases 
characterize both healthy sadness and depressive illness. Concurrent inhibition of overactive 
paralimbic regions and normalization of hypofunctioning dorsal cortical sites is suggested to 
be necessary for disease remission, whether facilitated by psychotherapy, medication, or 
electroconvulsive therapy. Also in bipolar disorder, the available data indicates that 
abnormalities in specific frontal-subcortical brain circuits seem likely (Strakowski et al., 
2000). 
 
2.1.5. Neurophysiological aspects 
Clinical neurophysiology examines the functions of the nervous system in the clinical setting. 
The neurophysiological effects of depression on the brain function can be evaluated by 
means of electroencephalography (EEG), by quantitative EEG (QEEG), by evoked potentials 
(EPs), by magnetoencephalography (MEG), by polysomnographic recordings and most 
recently by means of transcranial magnetic stimulation (TMS). Both spontaneous and event-
related activity can be studied as well as generators of that activity or the profile of the sleep. 
 
EEG. The spontaneous EEG activity has been divided into to the following frequency bands: 
beta activity (greater than 13 Hz), alpha rhythm (between 8 and 13 Hz), theta activity 
(between 4 and 7.5 Hz), and delta activity (less than 4 Hz) (see Niedermeyer, 1987). Theta 
and delta activity are the components of the slow-wave activity. The alpha rhythm occurs 
maximally over the posterior regions of the head and is blocked by eye opening. The 
presence of delta rhytms is considered to be a sign of pathology in an alert state. 
 
The role of neurophysiological methods in evaluation of the clinical brain function of 
depressed patients is not established as yet. The role of the EEG methods in the study of 
affective disorders has primarily considered to be in ruling out organic mental disorders 
(Brenner et al., 1989; Nuwer, 1997). In general, abnormalities in EEG are nonspecific. It has 
been concluded that EEG can help detect excess slow activity in organic disorders such as 
dementia but EEG is not yet able to help in the diagnosis of other disorders, such as 
schizophrenia or depression (Nuwer, 1997). In patients with endogenous major depressions, 
standard pretreatment clinical EEGs have been found to be abnormal in 19 percent of patients 
(Malaspina et al., 1994). It is further emphasized that the ability of any QEEG procedure to 
make psychiatric diagnoses or to discriminate between various groups of psychiatric patients 
and normal subjects is not well established (Nuwer, 1997). In contrast, Hoffman et al. (1999) 
considers that QEEG can be useful for the evaluation and understanding of psychiatric 
disorders by referring to a review by Hughes and John (1999). Regarding earlier studies, e.g. 
Abrams and Taylor (1979) have found that the proportion of abnormal EEGs was twice as 
great among schizophrenics as among affectives. Schizophrenics had more temporal 
abnormalities and affectives had more parieto/occipital abnormalities. Boutros (1996) have 
suggested that increased illness severity and increased number of medications and dosages 
may be accompanied with an increased amount of diffuse EEG slowing. One focus of 
neurophysiological studies in patients with mood disorders has been laterality or asymmetry 
regarding the brains hemispheres. In major depression, cerebral asymmetry (alpha 
suppression) as measured by EEG has been found to occur so that there is less left frontal 
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activation and greater right frontal activation (Davidson, 1992). On the other, Bruder et al. 
(1997) have found that the lateralization of EEG activation in depressed patients is dependent 
on the comorbid anxiety disorder in question.  
 
There is strong evidence that many psychotropic medications may modulate the brain’s 
function as measured by EEG. Epileptiform discharges on the EEG and increased slow-wave 
activity can be induced by neuroleptic medication, TCAs, and lithium (Holmes and 
Korteling, 1993). Lithium is one of the agents that induce most significant changes of the 
EEG (Struve, 1987). In contrast, chloralhydrate may induce only a little increase in beta 
activity (Holmes and Korteling, 1993). A dose-dependent effect of sertraline has been found 
on the pharmaco-EEG profile (Saletu and Grunberg, 1988). 
 
MEG. MEG is a modern neurophysiological method used in human brain research (Reeve et 
al., 1989; Hari, 1993; Hämäläinen et al., 1993; Salmelin and Mäkelä, 1995; Mäkelä, 1996; 
Reite et al., 1999). MEG recordings pick up tiny extracranial magnetic fields associated with 
electric currents in synchronously active cortical neurons. When a very sensitive instrument 
is used to measure these generated magnetic fields, the magnetic energy is converted back 
into an electrical signal. The detection of these very weak fields requires superconductivity, 
i.e. the use of a super quantum interference device (SQUID). In the SQUID devices, 
superconductivity is obtained by bathing the detectors in liquid helium at –269 degrees 
Celsius. Modern MEG instruments allow detection of magnetic field patterns produced by 
brain activitity simultaneously over the whole scalp. MEG allows non-invasive monitoring of 
ongoing human cortical activity on a millisecond time scale. The spatial resolution capacity 
of MEG is reasonable. Making measurements for patients is simple, and painless. MEG also 
has a capacity to localize generators of the cortical activity of the the brain. 
 
Both EEG and MEG evidently reflect postsynaptic currents in the pyramidal cortical cells. 
However, there are essential differences between EEG and MEG methodology in measuring 
the spontaneous brain activity. While EEG detects electric potentials, MEG picks up tiny 
extracranial magnetic fields associated with electric currents in synchronously active cortical 
neurons with a good spatial resolution (Hari, 1993). MEG is most sensitive to currents with 
components tangential to the head surface, i.e. to currents flowing predominantly in the 
fissural cortex, whereas EEG is sensitive to both radial and tangential currents (Hari, 1993). 
About two-thirds of the human cortex is embedded in fissures, and thus can be studied with 
MEG better than with EEG. Magnetic fields traverse the skull and scalp unaffected, whereas 
EEG signals are blurred by layers of different electric conductivities. Furthermore, the 
location of the reference electrode affects the recorded EEG signals, but MEG signals are 
reference free.  
 
The clinical utility of MEG includes presurgical mapping of sensory cortical areas and 
localization of hypoperfusion areas of the brains of stroke patients (Mäkelä, 1998; Reite et 
al., 1999). Psychiatric disorders are principally suitable for MEG research ( Mäkelä, 1996). 
However, little data exist e.g. on how depression affects spontaneous brain activity as 
measured by MEG. Reite et al. (1999) have found altered cerebral lateralization being 
associated with psychoses of schizoaffective disorder and bipolar I disorder. Llinas et al. 
(1999) have found that nine patients suffering from chronic, severe and therapy-resistant 
neurological or neuropsychiatric disorders (four patients with Parkinson’s disease, one 
patient with tinnitus, two patients with neurogenic pain and two patients with major 
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depression) had increased slow-wave rhytmicity in the theta range, in conjunction with a 
widespread and marked increase of coherence among high-and low-frequency oscillations.  
  
2.1.6. Treatment  
An active treatment of depression directed at remission, i.e. at removal of essentially all 
symptoms instead of reduction of the symptoms by 50% or some a greater percentage, i.e. to 
achieve response (see APA, 2000), is an important task in improving the long-term prognosis 
in depression (Baldwin, 2000). 
 
In the acute phase, pharmacotherapy, psychotherapy, a combination of medications plus 
psychotherapy, or ECT treatments can be used (see APA, 2000). The selection of an initial 
treatment modality should be influenced by both clinical (e.g., severity of symptoms) as well 
as other factors (e.g., patient preference). If preferred by the patient, AD medications may be 
provided as an initial primary treatment modality for mild major depressive disorder. AD 
medications should be provided for moderate to severe major depressive disorder unless ECT 
is planned. A specific, effective psychotherapy alone as an initial treatment modality may be 
considered with moderate clinical confidence for patients with mild to moderate major 
depressive disorder. Cognitive behavioral therapy and interpersonal therapy are the 
psychotherapeutic approaches that have the best documented efficacy in the literature for the 
specific treatment for major depressive disorder. With substantial clinical confidence, the 
combination of a specific effective psychotherapy and medication may be useful as an initial 
treatment choice for patients with psychosocial issues, interpersonal problems, or a comorbid 
personality disorder together with moderate to severe major depressive disorder. In the acute 
phase, the response rates with AD medications often range from 50% to 75% of patients 
(APA, 2000). The proportion of patients with major depressive disorders who respond to 
ECT has previously been found to range from 80% to 90% (see Abrams, 1997). ECT should 
be considered with substantial clinical confidence for patients with major depressive 
disorders with a high degree of symptom severity and functional impairment or for cases in 
which psychotic symptoms or catatonia are present (see APA, 2000). With moderate clinical 
confidence, ECT may also be the treatment modality of choice for patients in whom there is 
an urgent need for response, such as patients who are suicidal or refusing food and 
nutritionally compromised (see APA, 2000). The presence of comorbid general medical 
conditions that preclude the use of AD medications, a prior history of positive response to 
ECT, and patient preference are other important considerations that may indicate the use of 
ECT (see APA, 2000). ECT is often used for depressive patients who have not responded to 
AD medication. Medication resistant patients may show at least a 50% likelihood of a 
satisfactory response to ECT (Prudic et al., 1990).  
2.2. Electroconvulsive therapy (ECT) treatment 
2.2.1. Development of modern ECT practice 
History. ECT is an electrical induction of a series of generalized motor seizures for 
therapeutic purposes. Before electrical induction of seizures in humans, non-electric 
convulsive treatments induced e.g. by camphor and pentylenetetrazol were used by von 
Meduna since 1934 (Kalinowsky, 1986; Endler, 1988). Meduna’s idea of convulsive therapy 
was based on the frequent observation that catatonics and other schizophrenic patients would 
temporalily lose their psychotic symptomatology after spontaneous seizures whatever their 
cause. Thus, ECT was originally applied to schizophrenics, and only later was it realised that 
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it gives even better results in patients with depression. ECT was first implemented in April 
1938 by Cerletti and Bini for a human patient who probably suffered from schizophrenia 
(Kalinowsky, 1986). Only the third stimulus, which was higher than the two first stimuli, was 
followed by a complete seizure, after which the previously mute patient began to talk. He had 
a good remission after a series of treatments and could be followed for two years. 
 
Change of use of ECT as a function of time. At the end of the 1950s, the use of ECT 
decreased considerably with the introduction of AD medication until the early 1980s 
(Thompson and Blaine, 1987). A survey of practice in California between 1977 and 1983 
indicated that 1.12 persons per 10000 in the general adult population were treated with ECT 
(Kramer, 1985). The rate was 3.86 persons per 10000 among people aged 65 years and older. 
The overall increase in the use of ECT in the United States between 1980 and 1986 was fully 
attributable to its greater use in elderly patients (Thompson et al., 1994). The authors suggest 
that this increase occurred because of cardiovascular and other relative contraindications to 
AD medication in the elderly. In Finland, ECT was introduced as early as the end of the 
1930s (Achte, 1983). Huuhka et al. (2000) investigated the clinical use of ECT in the 1940s, 
1960s, and 1990s in Pitkäniemi Hospital. The authors found that the use of ECT decreased 
from about 14% to 2% of all inpatients between the two first time points but remained at the 
same level between the two latest data points. Over the last few years ECT has become a 
routine method for patients hospitalized because of depression in many countries. 
 
Attitudes and ethical aspects. There exists a lot of negative attitudes against ECT 
(Harrigan, 1999). It has been suggested that ECT is an unscientific treatment and a symbol of 
authority of the old psychiatry. Movies that deal with ECT have had a negative influence 
towards ECT. ECT has been shown on film as a progressively more negative and cruel 
treatment, leaving the impression of a brutal, harmful, and abusive manoeuvre with no 
therapeutic benefit (McDonald and Walter, 2001). Furthermore, there seems to be a 
significant negative biases against ECT among medical students. As high as forty percent of 
the students feel that psychiatrists often misuse ECT, while 31% actually thought ECT was 
used to punish violent or uncooperative patients (Clothier et al., 2001). Joyce Jackson 
(1995), who has been treated with ECT, emphasizes that the stigma that she feel as a result of 
having had ECT is not only the most severely adverse effect but also the only long-term 
adverse effect that she have experienced from ECT.  
 
Recent reports of the ethics of ECT focus on the necessity to obtain informed consent from 
the patients (APA, 1990; Reiter-Theil, 1992; see Royal College of Psychiatrists, 1995; 
Ekholm and Heikman, 1999; see APA, 2001). This method guarantees the rights of the 
patients by best means and also necessitates the physicians to give the patients their best 
available information on ECT.  
 
Low rates of use of ECT in Finland. In addition to the study of Huuhka et al. (2000), there 
are three studies which show a low use of ECT in depressive patients. Isometsä et al. (1994) 
have found that among suicide victims with current major depression 3% had received ECT. 
Suominen et al. (1998) have found that none of the suicide attempters with major depression 
had received ECT treatment either during the month just before their attempted suicides or 
during a one-month period after the attempt. Among Finnish patients with major depression 
who were granted a disability pension, 11 (4%) of the 277 patients had received ECT 
(Isometsä et al., 2000). 
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Indications for ECT. Depressive states are the main indication for use of ECT at present 
(see Royal College of Psychiatrists, 1995; see APA, 2001). Regarding patients with 
depression, ECT is often used for severe psychotic or melancholic depressions, in patients 
who are intolerant of or resistant to their AD medication, and/or in patients who are suicidal. 
ECT has an acute beneficial effect on suicidal patients but the data showing a long-term 
beneficial effect is weak (Prudic and Sackeim, 1999; Sharma, 2001). Catatonia, regardless of 
its cause, has been repeatedly treated successfully with ECT (see APA, 2001). For mania, 
ECT continues to be an effective treatment. A combination of ECT plus antipsychotic agents 
has been found to be at least as efficient as a combination of lithium and antipsychotic 
medication (Small et al., 1988). In drug-treatment-resistant cases, reported response rates are 
about 80% (Mukherjee et al., 1994; Daly, 1997). During the last years, interest in the use of 
ECT in schizophrenia has again increased (Tharyan, 1999). In the United States, 
schizophrenia and related conditions (schizophreniform and schizoaffective disorders) 
constitute the second most common diagnostic indications for ECT (see APA, 2001). Case 
studies concerning antiepileptic treatment with ECT have been reported since the 1940s in 
patients with epilepsy (Gonzalez, 1997). ECT has powerful anticonvulsant properties (Coffey 
et al., 1995b; Sackeim, 1999). The anticonvulsant effect has been associated with the ECT-
induced rise in seizure threshold. The rise in ST has found to be from 25 to 200% during a 
course of treatment (Sackeim et al., 1987a). Furthermore, ECT may be beneficial e.g. for 
symptoms of patients with idiopathic Parkinson’s disease (Andersen et al., 1987; Rasmussen 
and Abrams, 1991), for patients with neuroleptic malignant syndrome (Trollor and Sachdev, 
1999), for patients with refractory obsessive compulsive disorder, and for a subgroup of 
patients with chronic pain (Rasmussen and Rummans, 2002). 
 
Technical development. During the first years of ECT, the treatment was generally accepted 
in spite of the frequent complication of fractures. In 1951, succinylcholine became available 
as a safe muscle relaxant for used during ECT. To save the patient distress from paralysis of 
the respiratory muscles, barbiturate anesthesia prior to the muscle relaxant became an 
essential part of the ECT anesthesia. The place of unmodified ECT, i.e. treatment without 
anesthesia, has been questioned as being an unacceptable practice since the 1970s (McCleave 
and Blakemore, 1975).  
 
The amnestic effects of the conventional bitemporal (BT), i.e., bilateral (BL) sine wave ECT 
has been a great challenge for ECT research (see Abrams, 1997). Based on this valuable 
work, brief pulse stimulus and unilateral electrode placement has been widely introduced (see 
e.g Abrams, 1997). The beneficial effects of RUL ECT as compared with BT ECT on 
cognitive function has been emphasized (Weiner et al., 1986; see Abrams, 1997). 
 
An opportunity to evaluate the effects of BT stimulation exclusive of the temporal lobes 
arose with the suggestion of Inglis (1970) that seizures induced with electrodes placed over 
the front of the head should improve mood but have less effect on memory than other 
techniques. At the beginning of the 1970s, Abrams and Taylor (1973) used anterior bifrontal 
(ABF) ECT. Some years later, Weaver (1976) reported, using a theoretical model, that BT 
ECT induced maximal current density in frontal areas of the brain instead of the areas 
between the stimulus electrodes. ABF ECT disappeared from the ECT landscape until a 
modified version was introduced (Lawson et al., 1990; Letemendia et al., 1993; Bailine et al., 
2000). With this modern bifrontal (BF) ECT, the distance between electrodes is wider than 
with ABF. In addition to BF ECT, an asymmetric bilateral right frontotemporal left frontal 
stimulus electrode placement was introduced in the 1990s (Manly and Swartz, 1994; Swartz, 
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1994) but no controlled trials have been carried out with this ECT technique. Low-dose BF 
ECT as compared with low-dose RUL ECT and low-dose BT ECT has been shown to spare 
patients from cognitive side-effects without a concomitant impairment in efficacy (Lawson et 
al., 1990; Letemendia et al., 1993). Similar result have been reported by Bailine et al. (2000) 
using BT and BF ECT both dosed at equal doses, i.e. 1.5 times, relative to the seizure 
threshold level. However, the role of BF ECT has so far been considered to be experimental 
(see APA, 2001). 
 
Most of recent ECT research has been carried out on depressive patients. However, the 
required technique of ECT may be different e.g. for manic or schizophrenic patients. In the 
treatment of depression by ECT, the initial ECT stimulus dose can be chosen using two 
alternative methods (see Abrams, 1997). Firstly, the ECT dose can be given individually as 
obtained by a dose titration method (see e.g. Sackeim et al., 1987a) by which the individual 
seizure threshold is measured. Secondly, one can use a method of a predetermined dose, e.g. 
a fixed high dose method for RUL ECT treatment (Abrams et al., 1991; McCall et al., 
2000a), or a dose based on parameters which have some relationship with the seizure 
threshold level, e.g. the age of the patient (age-based dosing) (Swartz and Abrams, 1994; see 
Abrams, 1997). In contrast to RUL ECT, conventional BT ECT has not found to be as 
sensitive on the dosing methods (see Abrams, 1997). 
 
Practice guidelines for prescribing ECT. The APA has published recommendations for 
ECT on three different occasions (see APA, 1978; see APA, 1990; see APA, 2000). The first 
report aimed to standardize the practice of ECT. One of its most important contributions was 
to insist on the routine use of anaesthesia, muscle relaxation, and oxygenation in ECT. 
Furthermore, the first report favored unilateral ECT. The second report emphasized the 
importance of electrode placement/stimulus dose combination in optimizing therapeutic 
efficacy and minimizing cognitive effects. This report pointed out that using unilateral ECT, 
low electrical doses are usually associated with low efficacy. However, specific 
recommendations about how high above the threshold to deliver unilateral ECT could not be 
made, as studies concerning this issue were in a rather preliminary state at that time. The 
latest report provides recommended dosing range (2.5 to 6 times the threshold) for right 
unilateral ECT. Guidelines for prescribing ECT has been published twice by The Royal 
College of Psychiatrists (1989; 1995). Based on the recommendations by the APA (1990), 
Heikman (1995) has published recommendation on ECT for Finnish physicians. 
 
2.2.2. Mechanism of action 
ECT’s mechanism of action is still not fully understood. Over a hundred theories have been 
offered to account for the efficacy of ECT, and skepticism has been expressed about the 
possibility of uncovering its mode of action in part because ECT by provocation of 
generalized seizures produces a wide variety of effects to neurophysiological, to 
neurotransmitter/neurochemical, and to neuroendocrine systems. Therefore, it is essential to 
be able to isolate those neurobiological changes that accompany therapeutically effective 
forms of stimulation from nonspecific changes intrinsic to seizure induction. 
 
The functional changes induced by ECT are both ictal (recorded during ECT seizures) and 
interictal (recorded during waking). 
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There is a lot of data suggesting the role of frontal lobes in the mechanism of action of ECT. 
Weaver (1976) reported, using a theoretical model, that BT ECT induced maximal current 
density in frontal areas of the brain instead of the areas between the stimulus electrodes. 
Animal studies have pointed out the role of the frontal lobes in the mechanism of action of 
ECS (e.g. Nutt et al., 1989). Nutt et al. have found that ECS enhances a tonic throughput of 
norepinephrine in the frontal cortex and dopamine in striatum. Letemendia et al. (1993) have 
suggested that BF ECT by avoiding the temporal regions of the brain may spare both verbal 
and non-verbal cognitive functioning and by inducing maximal current density in the frontal 
regions may achieve full therapeutic advantage.  
 
During the seizures, using single photon emission tomography (SPECT) and blood-flow 
tracers, it has been found that ECT increases regional cerebral blood flow (rCBF) (Bolwig et 
al., 1977). The findings regarding interictal rCBF are not uniform; both reductions 
(Silfverskiöld et al., 1987; Nobler et al., 1994) and increases (Bonne et al., 1996; Bonne and 
Krausz, 1997) has been observed. Furthermore, the efficacy of ECT treatment has been 
reported to be associated both with a reduction, (Nobler et al., 1994) or an increase (Petracca 
et al., 1995; Bonne et al., 1996; Bonne and Krausz, 1997) of postictal rCBF. In positron 
photon emission tomography (PET) studies, ECT has been shown either to decrease the 
cerebral metabolic rate for glucose (CMRglu) (Henry et al., 2001), or have no effect on the 
CMRglu (Yatham et al., 2000). Thus, the findings on interictal CBF seem to be 
contradictory.  
 
In order to understand the mechanism of action of ECT, one has to also remember that ECT 
alleviates symptoms of depression, mania, psychosis, and motor disturbances. This may 
reflect the possibility that ECT does not act uniformly in all its indications (Fink, 1993a). 
 
In animal studies of electroshock treatments (ECS), seizure activity may last essentially 
longer than in humans and may be accompanied with different effects on the brain 
(Devanand et al., 1994). Second, the findings within animal studies seem to be inconsistent 
(Newman et al., 1988). Third, the relevance of neurochemical changes in the brains of 
normal rodents to the clinical effects of ECT in depressed or otherwise ill humans has been 
questioned (Lerer, 1999). Those are the three main reasons why I have excluded most of the 
animal studies conducted from this thesis.  
 
An interesting question is whether AD medication and ECT share some common 
mechanisms in their actions. The time to achieve maximal response may be more rapid with 
ECT than with psychotropic medication (Nobler et al., 1997; see APA, 2001). On the other 
hand, ECT and psychotropic medications may have some overlap in their mechanism of 
actions. Many resistant patients to TCAs respond to ECT but their response rates seem to be 
reduced compared to that of patients without established medication resistance (Prudic et al., 
1990). Failure to respond to one or more adequate medication trials have been shown to 
predict a diminished rate of ECT response (Prudic et al., 1996). Furthermore, the resistance 
to AD treatment may be dependent on the type of AD medication used: patients with 
resistance to TCAs have been found to be more resistant to ECT than patients with resistance 
to SSRIs (Prudic et al., 1996).  
 
ECT has to be given as a course of several treatments to induce its beneficial effects. In some 
patients, the response of the initial two treatments has found to be associated with the overall 
change at the end of the course (see Royal College of Psychiatrists, 1995). It is also found 
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that there is no any significant prophylactic value in giving extra ECT after clinical 
improvement in the hope of preventing relapse (Barton et al., 1973). The efficacy of ECT is 
not long-lasting. Sackeim et al. (2001) have found that without active treatment, virtually all 
remitted patients relapse within 6 months of stopping ECT.  
2.2.3. Neurophysiological aspects in mechanism of action of ECT 
Several studies are providing a growing body of evidence of the relationship between the 
response to ECT and both ictal and interictal EEG. The studies appear to be consistent in 
pointing to the importance of neurophysiological changes in the prefrontal cortex as a 
potential mediator of the antidepressant response to ECT (Krystal and Weiner, 1999).  
 
Seizure. It was long suggested that an induction of an epileptic seizure by ECT is essential 
for the efficacy and EEG changes of ECT (Ottosson, 1960). However, there nowadays exist 
strong evidence that the occurrence of a generalized seizure does not guarantee a good 
response to ECT (Sackeim et al., 1993). 
 
Seizure duration. Seizure duration per se is considered to be an unreliable guideline for 
effective treatment (Sackeim et al., 1987c; Sackeim et al., 1991; Nobler et al., 1993; Kales et 
al., 1997; Sackeim, 1999; see APA, 2001). In order to be a clinically adequate seizure, it has 
been suggested that a seizure should have a duration at least of 15-25 seconds (Weiner et al., 
1991; Krystal and Weiner, 1994; see Royal College of Psychiatrists, 1995; see APA, 2001). 
Importantly, brief seizures may be due to either insufficient or markedly suprathreshold 
stimulus intensity (Sackeim et al., 1991; Frey et al., 2001). On the other hand, short seizures 
are likely to occur in older patients (Sackeim et al., 1991; Boylan et al., 2000) as well as later 
in the ECT course (Kales et al., 1997). The process underlying the reduction in seizure 
duration through a course of ECT may not be related to antidepressant efficacy (Kales et al., 
1997).  
 
Ictal EEG findings. It has been shown that the ictal EEG characteristics of seizures induced 
by barely suprathreshold unilateral ECT (a low-efficacy treatment) are different compared to 
seizures induced by bilateral ECT and unilateral ECT administered at a high intensity relative 
to seizure threshold (high-efficacy treatments) (Krystal and Weiner, 1999). Treatments with 
high efficacy are accompanied with 1) higher amplitudes of 2−5 and 5−13-Hz activity 
immediately after the stimulus, 2) greater immediate poststimulus interhemispheric 
coherence, 3) a shorter time to the onset of the onset of high-amplitude slow waves, 4) 
increased amplitude of 2−5 and 13−30 Hz activity in the midictal portion of the seizure, 5) 
more regular midictal slow-wave shape (or signal predictability over time), 6) more 
pronounced postictal suppression, and 7) less postictal interhemispheric coherence.  
A relationship between postictal suppression and likelihood of clinical improvement has also 
been observed by Suppes et al. (1996) and by Nobler et al. (2000). However, in the study of 
Nobler et al. (2000) all associations between ictal EEG changes and clinical outcome were 
weak, and were dependent on manipulations of ECT technique. In contrast, Luber et al. 
(2000) found that effective forms of ECT resulted in a topography where ictal delta power 
was accentuated in prefontal EEG sites. Despite the relationship between clinical outcome 
and ictal EEG changes induced by ECT, the data has not been considered sufficient to give 
guidelines for a clinician for ECT dosing (see APA, 2001). 
 
Inter-ictal EEG slow-wave activity. EEG slow-wave activity induced by ECT has been 
investigated widely since 1940 (see Abrams, 1997). The global increase or lateralization of 
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this activity induced by modern brief-pulse stimuli is not associated with the efficacy of 
treatment (Weiner et al., 1986; Abrams et al., 1992; Sackeim et al., 1996). Instead, the 
efficacy has been related to induction of post-convulsive EEG delta (0.5-3.5 Hz) activity 
using QEEG over prefrontal regions (topography pattern 1) (Sackeim et al., 1996). Similar 
relationship with more primitive EEG techniques has been found as early as in the 1950s by 
Roth (1952) and by Fink and Kahn (1957). Fink and coworkers saw the development of the 
EEG slow-wave activity as evidence that a persistent change in brain chemistry had occurred, 
which was necessary but not sufficient for clinical improvement. The increase in EEG slow-
waves was suggested to indicate that the cerebral biochemistry was altered, thereby allowing 
physiological adaptive processes to modify the expression of psychoses. The changes in the 
EEG slow-wave activity have been shown to vary with the method of seizure induction, and 
with the number of seizure administered (see Abrams, 1997). Furthermore, the induced slow-
wave activity has been shown to resolve within several weeks after the treatment 
(Kolbeinsson and Petursson, 1988; see Abrams, 1997).  
 
Inter ictal MEG slow-wave activity. There are two studies which have found that the ECT-
induced slow-wave activity can be measured also by MEG (Salmelin et al., 1997; Sperling et 
al., 2000).  
 
Global EEG and MEG slow-wave activity and subcortical pacemakers. The global EEG 
slow-wave activity has been presumed to reflect an effect from subcortical pacemakers 
(Streriade et al., 1990). Using MEG, Llinas et al. (1999) suggest that the slow-wave activity 
in patients with Parkinson’s disease, with tinnitus, with neurogenic pain and with major 
depression may indicate presence of a thalomocortical dysrythmia. Even unilateral thalamic 
lesions have been shown to decelerate cortical MEG rhythms bilaterally (Mäkelä et al., 
1998). Under the influence of increased inhibition, thalamocortical neurons oscillate at about 
6 Hz instead of their normal frequency of around 10 Hz (Steriade et al., 1990). Inhibitory 
mechanisms are thought to be important in mediating the therapeutic effects of ECT 
(Sackeim et al., 1994; Sackeim et al., 1996).  
 
Modulation of the slow-wave activity. To understand how the cortical slow-wave activity is 
modulated may be even much more difficult than determing the electric field distributions 
induced by ECT. It has been suggested that adrenergic, cholinergic, and histaminergic 
neurotransmitter systems are involved in the expression of the slow-wave activity of the ECT 
process (see Fink, 1985). Regarding cholinergic neurotransmission, the relationship between 
changes in choline-containing coumpounds signal from hippocampus have been shown to be 
altered by ECT (Ende et al., 2000). The evidence of enhancement of serotonin transmission 
induced by ECT in the human central nervous system is not well known (Mann, 1998). In the 
most recent study, ECT in humans has not been found to induce an increase in the sensitivity 
of post-synaptic 5-HT1A receptors in the hypothalamus (Shapira et al., 2000). 5-HT1A-
receptor sensitization induces a decrease in the number of 5-HT2A receptors that are found to 
be elevated in depressive patients (Soares and Mann, 1997). Furthermore, a clinically 
successful ECT has found to be associated with changes in vascular perfusion and 
GABAergic neurotransmission (Mervaala et al., 2001). On the other hand, Krystal and 
Weiner (1999) point out that the anterior EEG slowing is not a categorical marker for 
therapeutic ECT but may actually reflect some other type of neuronal process, e.g. an 
increase in neurotrophic factor or a change in function of cortical-subcortical circuits, which 
is linked to clinical improvement. Subcortical involvement with ECT is based on both 
indirect and direct measures. As an indirect measure, ECT has found to accelerate heart rate 
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and raise blood pressure (see Abrams, 1997). As more direct measures, ECT has been found 
to have an effect on neurohormones (Sattin, 1999; Sundblom et al., 1999), on human 
thalamus as reflected in MRI T2 relaxation times (Diehl et al., 1994) and on human 
hippocampus as reflected in choline-containing coumpounds by MRS (Ende et al., 2000). 
 
During the seizures, using single photon emission tomography (SPECT) and blood-flow 
tracers, it has been found that ECT increases regional cerebral blood flow (rCBF) (Bolwig et 
al., 1977). The findings regarding interictal rCBF are not uniform; both reductions 
(Silfverskiöld et al., 1987; Nobler et al., 1994) and increases (Bonne et al., 1996; Bonne and 
Krausz, 1997) has been observed. Furthermore, the efficacy of ECT treatment has been 
reported to be associated both with a reduction, (Nobler et al., 1994) or an increase (Petracca 
et al., 1995; Bonne et al., 1996; Bonne and Krausz, 1997) of postictal rCBF. In positron 
photon emission tomography (PET) studies, the findings 24 hours after last ECT on regional 
cerebral metabolic rate for glucose (rCMRglu) have been negative (Volkov et al., 1988; Guze 
et al., 1991). ECT has been found to decrease the rCMRglu during the week after ECT 
(Nobler et al., 2000), or to have no effect on the rCMRglu after a one weeks follow-up 
period (Yatham et al., 2000).  
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Seizure threshold. The term seizure threshold (ST) refers to the minimum instrument setting 
(dose) required to induce a generalized seizure (see Royal College of Psychiatrist, 1995; see 
APA, 2001). Seizure threshold is affected by many factors affecting electrical impedance, 
and the excitability of brain neurons (Table 2). It is generally accepted that the most useful 
and valid measure of seizure theshold is in units of charge [coulomb, C = current (amperes, 
A) x time (seconds, s)] (see APA, 1990; see Royal College of Psychiatrist, 1995; see 
Abrams, 1997; see APA, 2001), but seizure threshold may also be described in units of 
energy (Joules, J), stimulus intensity (mC/s), voltage (volts/V) or current (milliampers, mA).  
 
Table 2. Factors affecting seizure threshold level  
   
Factor Effect References 
Age (increasing) Raise Sackeim et al., 1987a, b and c; 
Coffey et al., 1995a 
Anesthetic medication   
(increasing dose)  Raise  see e.g. APA, 2001 
Anticonvulsants Raise see e.g. APA, 2001 
AD medication Lower / No effect / 
Raise 
Warrington, 1992 / Boyer and 
Feighner, 1992 / Watanabe et al., 
1998 
β-blockers Raise ? see e.g. APA, 2001 
Benzodiazepines Raise? / No-effect  see e.g. APA, 2001 / Boylan et 
al., 2000  
Brain region: frontal / limbic strutures High /low Sackeim, 1994  
Caffeine (pretreatment given iv.) No effect  McCall et al., 1993a 
Dehydration Raise ? see e.g. Royal College of 
Psychiatrists, 1995. 
ECT-dynamic impedance (increasing) Lower Sackeim et al., 1994; Coffey et 
al., 1995a  
ECT- increasing number of treatments Raise Sackeim et al., 1987a, Coffey et 
al., 1995b 
ECT-previous course within last month Raise ? see e.g. Royal College of 
Psychiatrists, 1995 
ECT-electrode contact with scalp (poor) Raise see e.g. APA, 2001 
ECT-electrode placement (bilateral vs. unilateral) High vs. low Sackeim et al., 1987a, Coffey et 
al., 1995a 
ECT-stimulus pulse width (short vs. long) Lower Swartz and Manly, 2000 
Hyperventilation (low carbon dioxide saturation) Lower ? see e.g. Royal College of 
Psychiatrists, 1995. 
Neuroleptic medication Lower Coffey et. al., 1995a; Minabe et 
al., 1998; Woolley and Smith, 
2001  
Oxygen saturation of blood (low) Raise ? see e.g. Royal College of 
Psychiatrists, 1995. 
  
 
Sex: male / female Raise / lower Sackeim et al., 1987a, Coffey et 
al., 1995a 
Differences in thickness, anatomy, and Individual  Sackeim et al., 1994 
resistance of the skull   
  
 
Theophyllin Lower ? see e.g. Royal College of 
Psychiatrists, 1995 
   
 
Regardless of how ST is defined, it is important to recognize that it is not absolute. The level 
for BT ST level has shown range from 25 mC to 800 mC or more and that for RUL ST level 
from 25 mC to 300 mC (Sackeim et al., 1991). 
 
Although the biological counterpart of the individual ST is not well known, there is evidence 
that ST may be a modulator of the effects of electrical stimulation on both clinical outcome 
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(Sackeim et al., 1993; Sackeim et al., 2000a) and neural tissue (Sackeim et al., 1996). 
Changes in appearance of frontal EEG slow-wave activity corresponding to the efficacy of 
ECT have been found to be dose-dependent relative to the seizure threshold level (Sackeim et 
al., 1996). Regarding prolactin response, a moderate dose (3 times ST-level) RUL ECT 
stimulation has been found to cause a larger prolactin response than low threshold-level 
treatment (Zis et al., 1993).  
 
Relationship between seizure duration and seizure threshold. In ECT, seizure duration is 
not a direct measure of a seizure threshold. For example, a decrease in the duration of 
seizures have been found in patients receiving BZD medication (Pettinati et al., 1990) but the 
effects of BZDs may be more complicated towards ST (Sackeim et al., 1991; Boylan et al., 
2000). On the other hand, seizure duration at the first ECT treatment has been found to be 
inversely related to RUL and BT ST levels (Sackeim et al., 1987c; Sackeim et al., 1991; 
Coffey et al., 1995a). The relationship between seizure duration and initial ST level has not 
yet been studied in BF ECT. 
 
Neurophysiological aspects in mechanisms of ECT-induced cognitive side-effects. There 
are some findings that suggest different mechanisms for the ECT-induced beneficial effects 
and cognitive side-effects. It has been suggested that ECT-induced memory impairment is to 
a large extent a direct effect of the electrical stimulus and not to the seizure in mediating the 
beneficial effects (Ottosson, 1960). On the other hand, Sackeim et al. (2000b) have 
suggested that the neural system subserving the therapeutic and adverse cognitive side-effects 
of ECT are distinct. The ECT-induced memory dysfunction has been suggested to result from 
neuronal insults due to excessive release of excitatory amino acids and activation of their 
receptors (Chamberlin and Tsai, 1998).  
2.2.4. Efficacy of ECT as shown by different types of studies 
The efficacy of ECT in major depression has been shown in open trials (see APA, 2001), in 
ECT vs. medication comparisons, in ECT vs. sham ECT studies, and in ECT technique 
studies.  
 
ECT vs. sham ECT studies. It has been shown that real ECT has a better outcome as 
compared with treatment with anesthesia but without electrical stimulus, i.e. sham ECT in all 
(Freeman et al., 1978; Johnstone et al., 1980; West, 1981; Brandon et al., 1984; Gregory et 
al., 1985) but one study (Lambourn and Gill, 1978). In the study of Lambourn and Gill 
(1978), brief-pulse unilateral ECT was not better than sham ECT.  
 
ECT vs. medication comparisons. ECT has found to be a more effective treatment than AD 
medication in mixed age and geriatric populations (Avery and Lubrano, 1979). In the meta-
analysis of Janicak et al. (1985), it is reported an average response rate to ECT that was 20% 
higher than that of TCAs and 45% higher than that of MAOIs. Markowiz et al. (1987) have 
shown that depressed patients given ECT had mean hospital stays that were 13 days shorter 
than those given AD medication. On the other hand, Piper (1993) consideres that the data on 
outcome between ECT and TCA medication is inadequate to support the claim that one 
treatment is superior to the other because of numerous methodological weaknesses in the 
studies. Later, in a comparison of elderly depressed patients treated with ECT or 
pharmacotherapy, Philibert et al. (1995) have found higher rates of mortality and significant 
depressive symptoms in the pharmacotherapy group after a long-term follow-up. 
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Furthermore, ECT has found to be superior to paroxetine in medication-resistant major 
depression in terms of both degree and speed of response (Folkerts et al., 1997).  
 
ECT technique studies. The outcome of ECT in the treatment of depression has been found 
to be highly dependent on the ECT technique used (Table 3). 
 
Table 3. Outcome of the recent ECT studies in depression 
 
 
    
  
ECT stimulus dosing method   Response  Reference 
BT, at 50% above ST   87 % for study completers  Petrides et al., 
2001 
BF and BT, 1.5 times ST level   Equal efficacy, BF induced less global cognitive impairment  Bailine et al., 2000 
RUL at 50%, 150% and 500% at 
above ST. BT at 150 % above ST. 
  65 % for both RUL at 500% above ST and BT at 150% above ST  Sackeim et al., 
2000a 
RUL at 2.25 times ST, and RUL at 
a fixed high dose (403 mC) 
  67% for fixed high dose and 39% for RUL 2.25  McCall et al., 
2000a 
RUL at 2.5 ST   Response rate 31%  Ng et al., 2000 
RUL ECT at 2.25 times ST and 
FHDM (403 mC) 
  The FHDM resulted in a faster response.   McCall et al., 1995 
Low dose RUL, BT, and BF ECT. 
No DTM. 
  BF ECT was superior to both BT and RUL ECT.  Letemendia et al., 
1993 
RUL ECT and BT ECT, both 
dosed both at just above ST level 
and at 2.5 times the ST level 
  The response rate for low-dose RUL was 17% as compared with 
43% for RUL at 2.5 the ST level, and 65 % for high-dose BT and 
63% for low-dose BT. 
 Sackeim et al., 
1993 
FHDM (378 mC) for RUL and BT 
ECT 
  No significant difference between RUL and BT ECT, although 
there was a trend for faster improvement with BT ECT. 
 Abrams et al., 1991 
Low-dose (relative to the initial ST 
level) BT and RUL ECT 
  BT was markedly superior in short-term symptom reduction.  Sackeim et al., 
1987b 
      
      
 
The selection criteria for depression-efficacy studies using ECT may have caused a major 
bias (McCall et al., 2000b). Most of the depressive patients treated in clinical practices are 
not included to those studies. On the other hand, a comparison between BF ECT and 
adequate doses of RUL ECT has not been carried out. BF ECT has been shown to spare both 
verbal and nonverbal cognitive functions better than RUL ECT treatment if the stimulus is 
dosed just above individual seizure threshold (Lawson et al., 1990; Letemendia et al., 1993). 
The ST level RUL ECT which has been used as a comparison group for BF ECT has shown 
to have a poor outcome in the treatment of major depression (Sackeim et al., 1993). 
 
2.2.5. Side-effects and contraindications 
ECT is generally a safe treatment. Cognitive and cardiovascular side-effects are the most 
important ones. Although no absolute contraindication exists for ECT (see APA, 2001), the 
risk/benefit analysis must be done especially carefully with patients who may have increased 
intracranial pressure, or recent myocardial infarction.  
 
Brain damage. Structural brain imaging and postmortem neuropathologic studies provide no 
evidence that ECT produces brain damage (Coffey 1991 et al.; Coffey, 1994; Devanand et 
al., 1994). A classic amnestic syndrome involving anterograde and retrograde amnesia 
implicates a dysfunction in medial temporal lobe structures, especially the hippocampus 
(Squire, 1986; Sackeim et al., 1992; Sobin et al., 1995). ECT is not likely to induce 
hippocampal atrophy or cell death, which could be reflected in the N-acetylaspartame signal 
(Ende et al., 2000). On the other hand, measurement of magnetic resonance imaging T2 
relaxation times have been found to be increased in the thalamus after ECT (Diehl et al., 
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1994). The increased T2 relaxation times reflect increase in brain water content perhaps 
secondary to a breakdown of the blood-brain barrier. This process may be related to the 
memory impairment following ECT. 
 
Cognitive side-effects. ECT is associated with a transient postictal confusional state and 
with a longer period of anterograde and retrograde memory interference (see Abrams, 1997). 
The anterograde memory impairment, involving rapid forgetting of newly learned material, 
typically resolves in a few weeks after cessation of treatment (Stoudemire et al., 1995). Some 
degree of retrograde amnesia, involving loss of memory for information learned before ECT, 
may be long-lasting, particularly for recent memories, at least for patients receiving bilateral 
ECT (Weiner et al., 1986; McElhiney et al., 1995; see Abrams, 1997). Patients occasionally 
report more pervasive and persistent cognitive disruption, the basis of which is uncertain 
(Squire and Slater, 1983; Squire, 1986). The effects of ECT on non-memory cognitive side-
effects are not well studied. In most cases, cognitive functioning after recovery from the 
acute effects of ECT becomes better than prior to ECT (Krueger et al., 1992; Calev et al., 
1995; Brodaty et al., 2001). This may be due to recovery from the cognitive impairment 
caused by the depression. Brodaty et al. (2001) suggest that that mechanism is present even 
in elderly patients, i.e. for old (≥ 65 years) and for very old (≥ 75 years) patients. 
Squire and Zouzounis (1986) have suggested that the advantage of brief-pulse ECT on 
memory function in clinical practice is probably achieved only if treatment is dosed close to 
the individual seizure threshold. More recently, Sackeim et al. (1993) have shown that RUL 
ECT treatment with stimuli dosed at 2.5 times the seizure threshold level compared with that 
to threshold-level treatment induces a longer immediate disorientation phase, which increases 
the risk of retrograde amnesia following ECT (Sobin et al., 1995). On the other hand, 
according to Abrams (2002) there is no clear evidence in the literature that some long-term 
cognitive side-effects persist after brief-pulse ECT.  
 
Mortality. When mortality occurs with ECT, it typically happens immediately after the 
seizure or during the posictal period. The rate of mortality is estimated to be approximately 
the same as that associated with minor surgery (see APA, 2001). Published estimates from 
large and diverse patient series over several decades report up to 4 deaths per 100000 
treatments (see APA, 2001). Regarding longitudinal follow-up studies, some evidence has 
shown that mortality rates following hospitalization are lower among depressed patients who 
received ECT than among patients who received other treatment modalities or no treatment at 
all (Avery and Winokur, 1976; Philibert et al., 1995) although there is also a report that 
found no advantage for ECT (Black et al., 1989). 
 
Cardiovascular complications. ECT may cause a variety of cardiovascular complications 
including cardiac arrest, arrhytmias, ischemias, hypertension, and hypotension (Dec et al., 
1985; see APA, 2001). Cardiovascular complications are the most common cause of medical 
morbidity and mortality with ECT in those presenting cardiovascular disease (Zielenski et al., 
1993). Myocardial ischemia can be produced by hemodynamic changes during ECT in 8% of 
patients not known to have preexisting cardiac dysfunction (Alexopoulos et al., 1984). 
‘Recent’ myocardial infarction is believed to represent a risk for reinfarctation during ECT 
(see APA, 2001). The concept of ‘recency’ is, however, difficult to define. For example, the 
risks at six weeks after a mild myocardial infarction without adverse sequaele may be less 
than those present at six months after a severe, complicated infarction.  
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Prolonged apnoea. This is a rare condition accompanied with slow metabolism of 
succinylcholine (Packman et al., 1978). 
 
Prolonged seizures. The lengths of seizures defined as prolonged ones, are those longer than 
200 seconds (Coffey et al., 1995a), longer than 180 seconds (see APA, 2001), and longer 
than 120 seconds (Greenberg, 1985; see Royal College of Psychiatrists, 1995; see Abrams, 
1997). Prolonged seizures may be harmful especially for brain function and therefore they 
should be terminated either with iv-bzd or with the anesthetic used (see APA, 2001). Fink 
(1993b) has suggested that up to 1% of induced seizures may be prolonged. Coffey et al. 
(1995a) have found that 7% of their patients had prolonged EEG seizures. The frequency of 
prolonged EEG seizures has reported to be nearly 18% in the study of Mayur et al. (1999). 
They conclude that there was a potential risk of missing prolonged EEG seizures in 6.4% of 
the patients if motor monitoring alone was used. 
 
Tardive seizures. They are spontaneous seizures that occur within hours after ECT. This 
condition must be remembered in cases where the consciousness or vital functions of an 
ECT-patient are disturbed especially later on the treatment day (see APA, 2001). 
 
Nonconvulsive status epilepticus. ECT may be accompanied with an abrupt onset of 
delirium, unresponsiveness or agitation (Solomons et al., 1998). If not detected, epileptic 
activity without motor manifestations may cause severe brain damage. 
 
Cerebrovascular complications. ECT-induced cerebrovascular complications are notably 
rare (Hsiao et al., 1987).  
 
Headache, muscle soreness and nausea. These are common, and short-lasting side-effects 
which are mainly treated by symptom-relieving agents (see APA, 2001). 
 
Hypomanic switch. ECT may switch a depressive episode to hypomania or mania (see APA, 
2001) in at most 4% of patients treated with ECT (Devanand et al., 1992).  
 
ECT may cause also other side-effects which are reviewed e.g. by APA (2001). 
 
2.2.6. Prediction of efficacy of ECT in depression 
No reliable biological marker exists to predict efficacy of ECT (see Abrams, 1997). 
Therefore, prediction of outcome of ECT in depression is based on the technique of ECT 
intended to be used and on the clinical characteristics of depressed patients. However, no 
significant clinical predictors were found for 130 patients with unipolar major depressive 
disorder treated at a university teaching hospital in the study of Lam et al. (1999).  
 
Age. Findings regarding the effects of age on short-term efficacy of ECT are inconsistent. 
Some studies have reported that advancing age can be used to predict good response to ECT 
(Black et al., 1993; Wesson et al., 1997; Tew et al., 1999; O’Connor et al., 2001) while other 
studies have not found this relationship (Brodaty et al., 2000), and other studies have found a 
more rapid response in younger patients (Shapira and Lerer, 1999).  
 
Subtype of depression. ECT has found to be highly effective in major depressive disorder 
with psychotic features (Kantor et al., 1977; Pande et al., 1990; Petrides et al., 2001). 
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However, Sobin et al. (1996) found that the therapeutic advantage of effective forms of ECT 
was similar across the depression subtypes; patients who lacked both psychosis and 
retardation showed this pattern. Regarding melancholia, recent research (Sackeim and Rush, 
1995; see APA, 2001) has not confirmed the previous finding that melancholic depression 
predicts a good response to ECT (Carney et al., 1965).  
 
Duration of episode. A long duration of a current depressive episode has been shown to 
predict a diminished rate of ECT response (Black et al., 1993; Prudic et al., 1996). 
 
Severity of depression. Patients with a less severe depression has found to have a poorer 
response to ECT (Hamilton and White, 1980).  
 
Secondary depression. It has been shown that patients with secondary depression are less 
likely to recover from an index depressive episode (Coryell et al., 1985) and are more likely 
to receive inadequate treatment (Black et al., 1987) than patients with primary major 
depression. Moreover, patients with secondary depression have been found to have a poorer 
response to ECT treatment than patients with a primary depressive disorder (Davidson et al., 
1980; Zorumski et al., 1986; Black et al., 1987; Black et al., 1993). Zorumski et al. (1986) 
found that patients with alcohol dependence and secondary depression had a favorable 
response to ECT. However, concurrent alcohol dependence diminishes the likelihood that 
depression will respond to treatment (Mueller et al., 1994). 
 
Comorbid personality disorder. Patients with and patients without a personality disorder 
have been found to have similar short-term response to ECT (Zimmerman et al., 1986). On 
the other hand, depressed patients with borderline personality disorder may have a poorer 
outcome on some measures (DeBattista and Mueller, 2001). After a 6-month follow-up 
period, depressed patients with a personality disorder have been found to be more 
symptomatic (Zimmerman et al., 1986) although the acute phase of depression may have 
been effectively treated with ECT (DeBattista and Mueller, 2001).  
 
Use of psychotropic medication during ECT. When patients take BZDs during a course of 
unilateral ECT, the maximum therapeutic response may be compromised (Pettinati et al., 
1990). Combining ECT and antipsychotic agents may have synergistic effects (Klapheke, 
1993). There is little known about the combined clinical effects of AD medication and ECT 
(Pritchett et al., 1993). 
 
Resistance to antidepressant medication. Patients who had failed to respond to adequate 
pre-ECT pharmacotherapy have found to be substantially less likely to respond to ECT than 
patients who had not received adequate pharmacological trials before ECT (Prudic et al., 
1990; Prudic et al., 1996). This relationship was not found in the study of Lam et al. (1999). 
In the most recent study, Huuhka et al. (2000) have found that only 56% of the highly 
selected treatment refractory patients with depressive disorders responded to ECT in 1997 in 
contrast to the fact that almost all unselected depressive patients in 1955 and 1964 benefited 
from ECT.  
 
2.2.7. Prediction of adverse-effects of ECT in depression 
Patients with preexisting cardiac illness, compromised pulmonary status, or medical 
complications after earlier courses of anesthesia or ECT are especially likely to be at 
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increased risk (Zielinski et al., 1993; see Abrams, 1997). Furthermore, patients with low 
baseline heart rates might be likely to show bradyarrhytmia during treatment (Swartz and 
Manly, 1999). 
 
Patients vary considerably in the extent and severity of their cognitive side effects following 
ECT (see Abrams, 1997; Austin et al., 2001). Available information about the factors that 
contribute to the individual differences is limited (Pettinati and Rosenberg, 1984; Calev et 
al., 1989; Krueger et al., 1992; Austin et al., 2001). 
 
Age. Elderly patients may be at greater risk for more persistent confusion and greater 
memory deficits during and after ECT treatment ( see Abrams, 1997). 
 
Global cognitive impairment prior to ECT. Among depressed patients without known 
neurologic disease or insult evidence has indicated that the extent of pre-ECT global 
cognitive impairment (as measured by MMSE scores ) predicts the magnitude of retrograde 
amnesia for autobiographic information at long-term follow-up (see Abrams, 1997). 
 
Concomitant medication. Lithium and high doses of anesthetic medications may exacerbate 
ECT-induced cognitive side-effects (see Abrams, 1997).  
 
Post ECT disorientation. A longer immediate disorientation phase increases the risk of 
retrograde amnesia following ECT (Sobin et al., 1995). 
 
Known brain abnormalities. MRI findings of basal ganglia lesions and severe white matter 
hyperintensities have been linked to the development of an ECT-induced delirium (Figiel et 
al., 1990).  
 
ECT technique. Selection of ECT technique may increase vs. decrease the severity of 
adverse cognitive side effects, i.e use of sine wave vs. brief pulse stimulus waveform, use of 
BL vs. RUL electrode placement, use of grossly suprathreshold vs. low-dose stimulus 
intensity, spacing of treatments 3-5 times per week vs. to a fewer frequencies and use of 
multiple seizures per session vs. single seizure per session, respectively (see Abrams, 1997; 
see APA, 2001).  
 
2.2.8. Prescription of ECT in depression 
A decision to use of ECT should  be based on a risk/benefit analysis for the specific patient. 
This analysis considers the diagnosis of the patient, and the severity of the presenting illness, 
the patients treatment history, the anticipated speed of action and efficacy of ECT, the 
medical risks and anticipated adverse effects, and the likely speed of action, efficacy and 
safety of alternative treatments (see APA, 2000). Although no absolute contraindication 
exists for ECT (see APA, 2001), the risk/benefit analysis must be done especially carefully 
with patients who may have increased intracranial pressure, or recent myocardial infarction.  
 
Together with the risk/benefit analysis, concept of primary and secondary use of ECT should 
be considered according to recommendations by the APA (2001). Primary use of ECT, i.e. 
use of ECT prior to a trial of psychotropic agents, includes, but is not necessarily limited to, 
the following situations: where a need for rapid, definitive response exists on either medical 
or psychiatric grounds; or when the risks of other treatments outweigh the risks of ECT; or 
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when a history of poor drug response and/or good ECT response exists for previous episodes 
of the illness; or patient preference. The criteria for secondary use of ECT are as follows: In 
other situations, a trial of an alternative therapy should be considered prior to referral for 
ECT. Subsequent referral for ECT should be based on at least the following: treatment 
failure (taking into account issues such as choice of agent, dosage, and duration of trial, 
adverse effects which are unavoidable and which are deemed less likely and/or less severe 
with ECT, and deterioration of the patient’s condition such that the criterion (where a need 
for rapid, definitive response exists on either medical or psychiatric grounds) is met. In 
clinical practice, indications for secondary use than those of primary use are more often met 
in the treatment of depressed patients with ECT. 
 
Regarding use of ECT in special populations, ECT is a relatively safe and effective 
procedure in patients aged 75 or more (Gormley et al., 1998). Furthermore, ECT is a 
relatively safe and effective treatment during pregnancy if steps are taken to decrease 
potential risks (Miller, 1994). In young persons, there is limited information about use of 
ECT (Walter and Rey, 1999). 
 
Regarding use of ECT in high-risk populations, ECT is an effective and relatively safe 
procedure when careful attention has been paid to each patient’s medical and anesthesia 
needs (Rabheru, 2001). ECT is associated with a transient rise in intracranial pressure and 
blood-brain barrier permeability (see Abrams, 1997). For these reasons, patients with 
intracranial-space-occupying lesions, evidence of increased intracranial pressure or 
cerebrovascular fragility, e.g., unstable vascular aneurysm, are at substantially greater risk 
and should only receive ECT after careful general medical, neurological, or neurosurgical 
evaluation (Krystal and Coffey, 1997; see, APA 2001). Other high-risk-patients may be those 
with recent myocardial infarction, recent intracranial hemorrhage, retinal detachment, 
pheochromocytoma and an American Society of Anesthesiologists (ASA) level 4, i.e. a 
patient with an incapacitating systemic disease that is a constant threat to life or level 5, i.e. a 
moribund patient not expected to survive 24 hours with or without operation, ratings.  
There are many case reports showing the safety of ECT in high risk patients such as patients 
with a recurrent brain tumor (Kohler and Burock, 2001), with a metallic skull plate (Madan 
and Anderson, 2001), and with an automatic internal cardioverter-defibrillator (Lapid et al., 
2001). 
 
Pre-ECT evaluation. ECT treatment should be carried out according to the principles of the 
informed consent procedure (see APA, 2001). In order to reduce the fears against of ECT, 
the patient should have the possibility to visit the treating room and the personnel of the ECT 
treatment team. Furthermore, appropriate laboratory tests and physical examinations plus 
specialist consultations needed should be carried out according to the latest recommendations 
(see Royal College of Psychiatrists, 1995; see APA, 2001). 
 
Anesthesia for ECT. To prevent harmful effects of seizure on musculoskeletal and 
cardiovascular systems, the patients are given muscle relaxants (see APA, 2001). 
Succinylcholine is the most used agent. The use of a relaxant necessitates the use of an 
anesthetic. Methohexital, a short-acting barbiturate, has been the drug of choice over the last 
few decades. Methohextial is no longer manufactured and thiopenthone and propofol have 
replaced it. The seizures during propofol anesthesia are shorter than during methohexital 
(Swartz, 1992; Malsch et al., 1994; Martensson et al., 1994), and etomidate anesthesia 
(Stadtland et al., 2002). However, the reduction in seizure duration using propfol anestehesia 
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has not shown to impair the outcome of ECT treatment (Malsch, 1994; Martensson et al., 
1994). In addition to relaxant and anesthetic, an anticholinergic (atropine or glycopyrrolate) 
is often used for ECT anesthesia. The application of an electrical stimulus results in vagal 
stimulation regardless of whether a seizure is induced. This parasymphatetic discharge almost 
invariably results in decreased heart rate unless patients are premedicated with an 
anticholinergic agent (see Abrams, 1997). Seizure induction produces a sympathetic 
conversion from bradycardia. However, for various reasons, subconvulsive stimulation with 
increased risk to asystole can happen at any time during ECT. Beta-blockers by unopposing 
the parasympathetic discharge induced by ECT may increase the risk to asystole (McCall, 
1996). Oxygenation is recommended prior, during and after the ECT to prevent any harmful 
effects of ECT (see APA, 2001).  
 
ECT devices. Modern ECT devices deliver a bi-directional square wave brief-pulse stimuli 
and are equipped with EEG and ECG monitoring (see Royal College of Psychiatrists, 1995; 
see APA, 2001). The decision how the device is used for the treatment of patients, should be 
decided by the treating physician based on the clinical status of the patient.  
 
Electrode placement / stimulus intensity. The combination of electrode placement and 
stimulus intensity is the most important technical factor in treatment with ECT. Since the two 
cannot be separated in discussions of efficacy and cognition, they are essentially one topic 
(see APA, 2001). BT ECT may predispose to long-lasting cognitive side-effects. However, 
when a rapid effect of ECT is necessary, the BT ECT may be the optimal choice also today 
(see APA, 2001). In other cases, RUL ECT has been recommended since 1990 (see APA, 
1990). RUL ECT at a moderate dose (100-200%) above seizure threshold (ST) has been 
often used as the initial standard treatment based on the previous recommendations (see 
APA, 1990; see Royal College of Psychiatrists, 1995). On the other hand, Sackeim et al., 
(1993) have found that RUL ECT at the threshold-level dose has an extremely poor efficacy. 
Increasing the dose to 2.5 the seizure threshold level increases the efficacy of the RUL ECT, 
although not to the level of the BT ECT. In the most recent study of Sackeim et al. (2000a), 
high-dose RUL (6 times ST level) was as effective as BT ECT. BF stimulus has been shown 
to spare both verbal and nonverbal cognitive functions better than BT and RUL ECT 
treatment if the stimulus is dosed just above the individual seizure threshold (Lawson et al., 
1990). However, the place of BF ECT in the treatment of depressive patients has not yet been 
established. 
 
The initial ECT stimulus dose can be chosen using two alternative methods. Firstly, the ECT 
dose can be given individually as obtained by a dose titration method (DTM) (see e.g. 
Sackeim et al., 1987a) by which the individual seizure threshold is measured. Secondly, one 
can use a method of predetermined dose, e.g. a fixed high dose method for RUL ECT 
treatment (Abrams et al., 1991), or a dose based on parameters which have some relationship 
with the seizure threshold level, e.g. the age of the patient (see Abrams, 1997). Age-based 
dosing has two clinical applications. In the age method (AM), the dose (mC) equals the age 
(years) of the patient multiplied by 5.0 (Swartz and Abrams, 1994), and in the half-age 
method (HAM) the dose (mC) equals the age (years) of the patient multiplied by 2.5 (Petrides 
and Fink 1996). Unilateral ECT is more dose sensitive than BT ECT (see APA, 2001). In 
routine clinical BT ECT practice, Gangadhar et al. (1998) have suggested that the ‘formula’ 
method using age alone may be appropriate.  
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There is an ongoing debate on whether to use the DTM or the method of predertimened dose. 
Those who are for the DTM, emphasize the value of individual dosing. Those who are 
against the DTM, consider that the DTM is a technically difficult method, the DTM may be 
an unreliable method because many factors affect ST level, and subconvulsive stimuli, which 
are a part of the DTM method, may be accompanied with cardiovascular or cognitive side-
effects (see Royal College of Psychiatrists, 1995; see Abrams, 1997; see APA, 2001). In the 
recent studies, subconvulsive stimulation has not been found to induce any adverse cognitive 
(Prudic et al., 1994) or severe cardiovascular consequences (McCall et al., 1994).  
 
Monitoring the ECT seizure. Monitoring seizure activity is done routinely by modern ECT 
devices. EEG directly measures the brains electrical activity and therefore, it has suggested 
that EEG is the standard against which other techniques must be measured (see Abrams 
1997; Mayur et al., 1999). Furthermore, prolonged and tardive seizures may not be 
accompanied with motor manifestations (Parker et al., 2001). On the other hand, 
interpretation of EEG requires experience and education. EEG may be sensitive to different 
artifacts. Furthermore, EEG amplitude may decrease gradually rather than abruptly, and then 
it is difficult to determine exactly when the seizure ends. In these cases, the practitioner will 
need to rely on clinical signs (resumption of spontaneous breathing, and return to baseline 
heart rate) to know that the seizure is over. If low ECT stimuli are used, it is possible that 
there exist no recordable EEG seizure activity. This may be due to the low EEG seizure 
regularity at the ST-level (Krystal et al., 1993; McCall, 1998). In cases of low seizure 
regularity, the individual waves may bear no resemblance to their immediate neighbours.  
 
Motor seizure monitoring can be done by direct visual observation or by inflating a blood 
pressure cuff above the peak systolic pressure to block of distribution of relaxant to a distal 
part of the limb in order to see an unmodified seizure (see Royal College of Psychiatrists, 
1995; see APA, 2001).  
 
Modern ECT practice includes both EEG and motor seizure monitoring methods.  
In addition, seizure duration can be estimated using ECG. ECT-induced tachycardia has been 
found to be highly correlated with both motor and EEG seizure estimates (Larson et al., 
1984). 
 
Frequency of treatments. ECT is typically administered three times weekly; less frequent 
administration has been associated with less cognitive impairment but also a prolonged 
period until onset of action (Lerer et al., 1995; Shapira et al., 1998; see APA, 2001). The 
change between the two methods can be done based on the clinical status of the patient. 
 
ECT and concurrent medication. Because of a lack of controlled studies, the clinician 
often has to make decisions based solely on clinical needs. It is often necessary to provide 
symptomatic relief against anxiety at least until the therapeutic effects of ECT are manifest. 
There is a standard recommendation that BZD’s are to be avoided in patients receiving ECT 
(see APA, 1990). Concomitant use of BZDs and ECT may lessen the efficacy of treatment 
(Ottosson, 1960; Standish-Barry et al., 1985; Greenberg and Pettinati, 1993). The maximum 
therapeutic response may be compromised especially during a course of unilateral ECT 
(Pettinati et al., 1990). However, the empiric data on the impaired efficacy with BZD and 
ECT is weak (Sackeim et al., 1991), and there is some evidence that depressed patients with 
marked anxiety may, in any case, have a poorer rate of ECT response (Pande et al., 1990). If 
BZDs are used, the preferred agent is lorazepam in doses up to 3 mg/day with a minimum 
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duration of between 8 to 12 hours between the last administration of medication and ECT 
administration (Sackeim et al., 1991). 
Combining ECT and antipsychotic agents may have synergistic effects (Klapheke, 1993). 
The 1990 APA report cautioned against concomitant use of AD medication and ECT. 
However, there is in general little known about the combined clinical effects of ADs and 
ECT (Pritchett et al., 1993) but also little is known about the synergistic effects between AD 
medication and ECT (Nelson and Benjamin, 1989; Lauritzen et al., 1996). In one male 
patient, the combined use of venlafaxine and ECT has been found to cause a prolonged 
bradycardia (Agelink et al., 1998) whereas Bernando et al. (2000) have found that combined 
venlafaxine and ECT appears to be safe. For patients with severe and recurrent mood 
disorder, complete discontinuation of lithium may not be advisable (APA, 2001). The 
decision to continue lithium during ECT should be made on a case-by-case basis. It is 
possible that the risk of neurotoxity increases at higher serum lithium levels and that it might 
be reduced by keeping lithium levels in the low-to-moderate therapeutic range. 
 
Continuation / maintenance ECT. High relapse rates after ECT are perhaps the biggest 
problem of the ECT practice (Sackeim et al., 2001). Petrides et al. (1994) have found that in 
psychotic depression, about 42 percent of the patients had a relapse of depression during a 
one year follow-up period. In the most recent study by Sackeim et al. (2001) it was found 
that without active treatment, virtually all remitted patients relapse within 6 months of 
stopping ECT. High relapse rates are not surprising given that most patients are medication 
resistant, and ECT is usually withdrawn at the moment it becomes effective (McCall, 2001). 
Although continuation/maintenance ECT is an option in preventing relapse, it may not be a 
practical solution for persons still in their productive years, and it is resource-intensive 
(McCall, 2001). The strategies regarding continuation/maintenance ECT clearly need future 
studies ( see APA, 2001; Sackeim et al., 2001). 
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3. AIMS OF THE STUDY 
The general aim of this thesis was to study neurophysiological changes and clinical outcome 
in depressed patients receiving either RUL or BF ECT. BF ECT is an experimental ECT 
technique which has so far found to have a low cognitive risk/benefit ratio. The mechanism 
of action of ECT is still not fully understood but recent EEG data indicate that ECT-induced 
changes in terms of slow-wave activity over prefrontal lobes may play an essentially 
important role. Regarding ECT dosing, there is an ongoing debate on the optimal 
combination of the placement and dose of the stimulus. One central question concerns the 
value for estimating an individual seizure threshold, i.e. the use of the DTM, as compared 
using a method of a predetermined dose based e.g. on the age of the patients (age method, 
AM) or use of a fixed high-dose (FHDM) method. Furthermore, both clinical and 
neurophysiological aspects of the measured seizure threshold need to be studied more 
specifically. Unfortunately, recent ECT efficacy studies have excluded many groups of 
patients who are treated with ECT in clinical practice. Therefore, ECT research is clearly 
needeed in a pragmatic sample of depressive patients. 
 
The specific aims of the studies (I-V) are as follows: 
 
1. To study ECT-induced changes in the spontaneous MEG slow-wave activity (0.5-3 Hz and 
3-7 Hz) both of the frontal and occipital cortex, and to study further, if the induced changes 
might have any relationship to the clinical outcome on the ECT treatment. 
 
2. To study the relationship between initial seizure threshold and seizure duration in 
depressive patients for RUL and BF ECT. 
 
3 To compare the DTM and the predetermined dose methods in terms of stimulus dose in 
relation to the initial seizure threshold for RUL and for BF ECT patients. Regarding 
predetermined dose methods, AM was used both for RUL and BF patients and FHDM only 
for RUL patients.  
 
4 To compare the outcomes for low-dose BF ECT, high-dose RUL ECT, and moderate dose 
RUL ECT in patients with a pure major depression. 
 
5 To study the effectiveness of RUL ECT in a pragmatic heterogeneous patient population as 
compared with that in patients with pure major depression. 
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4. PATIENTS AND METHODS 
4.1. Study design 
This prospective study was carried out between November 1994 and February 1997 in two 
phases, i.e. in a preliminary phase (from November 1994 to October 1995), and in a 
randomized phase (from October 1995 to February 1997). All the study patients were more 
than 20 years old and had been hospitalized because of depression at the Lapinlahti Hospital 
of the Department of Psychiatry of Helsinki University Central Hospital, and they gave their 
informed consent for the study. During the same time period, there were a total of 1655 
hospitalizations at the Lapinlahti Hospital.  
 
All ECT treatments were given or supervised by an ECT treatment unit (ECT-T-U). The 
ECT-T-U included two treating psychiatrists [Eila Sailas, and Pertti Heikman (P.H.)], an 
ECT treatment nurse (Inge Taskinen), and the anesthesiologists from the Intensive Care Unit 
of Helsinki University Central Hospital. Pre-ECT evaluation for standard short-term 
generalized anaesthesia was done for all the patients referred by the attending physicians to 
the ECT-T-unit. All study patients were stimulated using standard RUL and BF titration 
schedules (Table 4. ). 
 
Table 4. The dose titration schedules for RUL and BF ECT 
 
           
 RUL stimulus BF stimulus 
           
 
Dose Current Pulse 
width 
Frequency Duration Dose Current Pulse 
width 
Frequency Duration 
 mC A ms Hz s mC A ms Hz s 
First  
level 
25.2 0.9 1.0 30 0.47 50.4 0.9 1.0 30 0.93 
Second 
level 
50.4 0.9 1.0 30 0.93 100.8 0.9 1.0 30 1.87 
Third 
level 
75.6 0.9 1.0 30 1.4 151.2 0.9 1.0 50 1.68 
Fourth 
level 
100.8 0.9 1.0 30 1.87 201.6 0.9 1.0 50 2.24 
           
The patient is stimulated using an increased stimulus dose with an interval about 30 s between the stimuli until she or he has a 
generalized ECT-induced epileptic discharge. 
The seizure threshold is defined as the ECT stimulus which elicits a generalized convulsive activity lasting for at least 25 s. 
           
 
All the clinical evaluations and the pre-ECT EEG recordings, pre-ECT MRI recordings and 
MEG recordings prior, during and after ECT were done blinded to ECT treatments.  
The attending physicians completed a structured questionnaire formulated for the pre-ECT 
evaluation according to the recommendations of the APA (1990). This questionnaire was 
used during the whole study period as a referral (N = 140) to the ECT-T-U.  
Fifty-eight patients were not recruited to the study. Twenty-three patients did not receive 
ECT: twelve patients refused to have ECT, four patients had present alcohol abuse, one 
patient had present abuse with BZDs, and six patients were in partial remission. Thirty-five 
patients were excluded: two patients did not give their consent to the study, five patients 
received outpatient ECT, one patient received BT ECT for schizophrenia, three patients were 
treated because of severe catatonia at the Meilahti hospital with BT ECT, one patient could 
not have methohexital anesthesia due to methohexital allergy, fourteen patients were not 
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stimulated with the standard RUL and BF ECT schedule (in five cases due to technical 
problems, in two cases due to a higher than the standard initial RUL dose and in seven cases 
due to a higher initial BF dose), six patients were treated with age based dosing, and three 
patients continued with their AD medication. Thus, 82 patients entered the study. DSM-IV 
diagnoses are based on the semi-structured clinical interviews made either by E.S. or P.H, 
always prior to ECT. The collection of psychiatric history included a symptom checklist for 
criteria of major depressive episode.  
 
The psychotropic medication which had failed to achieve remission, was continued with 
stable doses during the entire ECT treatment course to eliminate the withdrawal effects of 
medication on the MEG signal. In studies II and III, psychotropic medication was either kept 
stable or reduced by the attending physician. For clinical studies IV and V, the antidepressant 
medication had to be discontinued beforehand. The minimum wash-out period was five days.  
For an antidepressant trial to be considered adequate in Studies IV-V, the threshold for 
sufficient duration was a minimum of 4 weeks at or above the threshold for the usual dosages 
of antidepressants (see APA, 2000). 
 
The study protocol was approved by the Ethics Committee of the Department of Psychiatry 
of Helsinki University Central Hospital according to the principles of the Helsinki 
declaration. 
4.2. Patients 
All the 82 patients who entered the study fulfilled the inclusion and exclusion criteria for 
studies II and III as shown in Table 5.  
 
Table 5. Inclusion and exclusion criteria to the Studies I - V   
 Study I  Studies II and 
III 
Study IV Study V 
 
     
 
Time period used for inclusion the patients to 
Studies I-V (month/year) 
6/95-6/96 11/94-2/97 10/95-2/97 10/95 -2/97 
 
    Group 1 Group 2 
Number of included patients 7 82 24 16 24 
      
Inclusion criteria      
Age (years) 20-50 > 20 > 20 > 20 > 20 
Major depressive episode yes not necessary yes yes yes 
Unipolar (U) / bipolar (B) depression U U and B U and B U and B U and B 
Severity of depression on MADRS or HDRS scale  MADRS >25 no limit HDRS > 16 HDRS > 16 no limit 
AD wash out  at leat 5 days prior to ECT No 
not necessary
a
 
yes yes yes 
      
Exclusion criteria      
Previous ECT during a 6 or 3 months’ period 6 months  3 months 3 months 3 months 3 months 
Pre-ECT EEG recording (abnormal/normal) abnormal No criteria no criteria no criteria no criteria 
Pre-ECT MRI imaging (abnormal/no criteria) abnormal No criteria no criteria no criteria no criteria 
Lithium medication  yes no no no no 
History of rapid-cycling bipolar illness
b
 
yes no yes yes no 
History of alcohol abuse during previous year yes no yes yes no 
History of schizophrenia yes no yes yes no 
History of schizoaffective disorder yes no yes yes no 
History of any other concurrent psychosis yes no yes yes no 
History of a severe medical illness yes no yes yes no 
History of a neurological illness yes no yes yes no 
 
  
a 
The AD medication was either stable or reduced by the attending physician.   
 b 
At least four mood episodes occur during the previous 12 months’ period.
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The selection criteria for studies I, IV and V are also shown in Table 5. 
In Group 2 of Study V, four patients had had a mild major depressive episode, eight patients 
had a history of alcohol abuse during the previous year, six patients had a history of 
schizophrenia, schizoaffective disorder or another psychotic disorder which was not part of 
the mood disorder (four patients had psychotic disorder not otherwise specified, and two 
schizoaffective disorders), two patients had a history of a neurological illness (one patient 
had cerebellar ataxia, and the other ischemic cerebrovascular disease) and four patients had a 
history of a severe medical illness (three patients had hypertensive cardiovascular disease 
with concomitant risk factors: one had an aortic homograft, one a history of epilepsy, and one 
a risk for esophageal reflux, and one patient had coronary artery disease with coronary artery 
bypass grafting).  
 
4.3. Technique of the ECT treatment 
Prepare for ECT. Patients were given an opportunity to express their concerns and 
questions on ECT treatment to the attending physicians, psychiatric nurses, and the members 
of the ECT-T-U according to the recommendations by APA (2001). The patients were 
prepared for ECT treatments in the same way during the whole study period. The stimulation 
sites were cleansed with alcohol, wiped dry, and thereafter conductive gel (Hellige) was 
applied over the treatment surfaces of the stainless steel electrodes. The static impedance 
(skin-to-electrode contact) was measured before each treatment. The impedance was 
according to the recommendation of the THYMATRON-DGx manual (Swartz and Abrams, 
1994) at least 100 and less than 3000 ohms prior to all stimulations.  
 
Anaesthesia. ECT anesthesia included standard medication, i.e., atropine (0.4 mg), 
methohexital (0.75 mg/kg), and succinylcholine (0.5 mg/kg). All medications were given 
intravenously. The doses of medications were allowed to be adjusted individually on clinical 
grounds. The patients were oxygenated (100% O2, 35% face mask), and their cardiovascular 
function (heart rate, and blood pressure) was monitored using a Cardiocap II anesthesia 
monitor (Datex).  
 
Stimulus electrodes. For RUL ECT, a flat and a concave stimulus electrode, and for BF 
ECT, two concave stimulus electrodes, both hand held and ~5 cm in diameter, were used.  
 
Electrode placements. In the RUL ECT, we used d’Elia ECT stimulus placement (d’Elia 
and Perris, 1970), whereas in the BF ECT, the midpoints of both electrodes were about 5 cm 
above the lateral angles of the orbits on both sides (Lawson et al., 1990; Letemendia et al., 
1993). 
 
Seizure threshold measurement. The initial ST level was defined as the ECT stimulus dose 
(mC) which elicited a generalized motor convulsive activity lasting for at least 25 s that could 
be observed by the ECT-T-U. The adjustment of the starting dose on the basis of electrode 
placement was based on the previous RUL (McCall et al., 1993b; Rasmussen et al., 1994) 
and BF (Letemendia et al., 1993) studies. The first stimulus (25.2 mC) in the RUL ECT 
group was the lowest stimulus level of the THYMATRON-DGx device, whereas the 
stimulus level in the BF ECT group (50.4 mC) was set to be lower than the standard initial 
dose (120 mC) used in the study by Letemendia et al. (1993). The schedules for the RUL and 
BF ECT were as follows: 25.2, 50.4, 75.6, and 100.8 mC for RUL ECT; 50.4, 100.8, 151.2, 
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and 201.6 mC for BF ECT (Table 4). The stimuli (pulse width 1 ms) were repeated at about 
30 s intervals until the patient had a generalized (bilateral) motor convulsive activity lasting 
for at least 25 s. The motor seizure duration was measured by an ECT nurse using a 
stopwatch from the end of the stimulus to the end of the last clonic movement. The ST was 
defined as that ECT stimulus dose of the titration procedure which elicited such a seizure.  
 
ECT was administered 3 times per week. In the second and subsequent treatments of study 
IV, the stimulus was dosed in the RUL ECT group either at five times the initial ST level 
(400% above the ST level, RUL ECT 5) or at 2.5 times the ST level (150% above the ST 
level, RUL ECT 2.5) and in the BF ECT treatment at the ST level (just above the ST level, 
BF ECT 1.0). For study V, RUL ECT 5 and RUL ECT 2.5 were used. The treatments were 
continued with fixed stimuli, making sure that the motor seizure duration exceeded 25 s. If 
the generalized motor seizure was shorter, the patient was restimulated after approximately 
60 s with a 25% greater charge, and if no seizure occurred, restimulation was given after 
about 30 s. 
 
ECT seizure monitoring. Our primary seizure monitoring method was direct visual 
observation of a motor seizure. One-channel THYMATRON EEG seizure monitoring was 
done with standard THYMATRON electrodes including measurement of seizure duration 
and also seizure quality measures, i.e. seizure energy index, seizure concordance index and 
postictal suppression index (Swartz and Abrams, 1994). Prior to each ECT treatment, the 
gain of the EEG channel was adjusted for each patient to obtain clearly visible recordings. 
Bifrontal linkage (Fp1-Fp2) was used in the preliminary phase, and right frontopolar (Fp2-
FM1) linkage was used both in the preliminary and randomized phase. The other channel of 
the Thymatron device was used for EMG recording. Due to an insufficient number of reliable 
EMG registrations, we could not use the EMG data for statistical analyses. 
Generally, the use of the cuff-method in motor seizure monitoring (Addersley and Hamilton, 
1953) is recommended (see APA, 2001). However, for this thesis, direct motor seizure 
monitoring was used. The seizure threshold measurement with up to three restimulations may 
take a longer time than other treatments during the ECT treatment course. Therefore, the 
cuff-method may include the potential risk of a prolonged ischemic period. An additional 
side-effect with the cuff-method may be the risk for fractures in patient with osteoporosis. 
Furthermore, the benefit of using the cuff method is dependent on the dose of relaxant used. 
With a succinylcholine dose of 1.0 mg/kg or more, motor movements of the ECT-induced 
seizure are generally mild and may be altogether absent (Weiner et al., 1991). Such a high 
dose is indicated e.g. in patients with abdominal aortic aneurysm (Goumeniouk et al., 1990). 
Partial muscle paralysis achieved with succinylcholine doses of 0.5-1.0 mg/kg has been 
shown in general to allow for direct observation of motor seizures (Enns and Karvelas, 
1995). Regarding absolute doses of succinylcholine, doses from 20 to 50 mg of 
succinylcholine have been found to give a safe degree of paralysis but still allow observation 
of the motor seizure (Letemendia et al., 1993). Furthermore, convulsive movements have 
been found in some cases to end later in other parts of the body than in the cuffed extremity 
(Barrington and Lambourn, 1987; Couture et al., 1988). ECT anesthesia for the Studies in 
this thesis included the standard low dose of succinylcholine (0.5 mg/kg). This dose was 
allowed to be adjusted individually on clinical grounds.  
 
ECT device. The same square-wave, brief-pulse, constant current device (THYMATRON-
DGx™, Somatics Inc., Lake Bluff, IL, U.S.A) was used for all patients.  
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4.4. Clinical evaluations 
Attending physicians. The attending physicians evaluated under supervision by the senior 
physician the clinical status of the patients prior, during, and after the course of treatment. 
The ECT treatment course was finished (IV and V) when 1) a patient had two or fewer of the 
nine symptoms for DSM-IV major depressive episode A criteria, or 2) no further 
improvement occurred after two consecutive treatments during the courses of ECT.  
 
Extra raters. Three extra raters (Irja Idman, Heikki Katila and Kristian Wahlbeck) evaluated 
the severity of a major depressive episode using the MADRS scale (I) and HDRS scale (IV 
and V) prior, during, and after the course of treatment. Interrater reliability between these 
three raters was tested thrice during the study.  
 
The psychiatric nurses. The psychiatric nurses used MMSE scales (Folstein et al., 1975) 
for evaluation of the global cognitive functionig (IV and V).  
 
4.5. EEG, MRI and MEG recordings 
This thesis includes neurophysiological data for depressive patients on spontaneous brain 
activity (EEG and MEG) prior to ECT. ECT-induced EEG activity was recorded ictally, i.e. 
during seizures. Between treatment sessions and after the course of ECT treatment, 
spontaneous brain acitivity was recorded by MEG. We have not used measurements of 
evoked potentials or polysomnographic recordings. 
 
A Siemens Magnetom SP 42 (Erlangen, Germany) was used to obtain the 1-Tesla magnetic 
resonance images (MRI) prior to ECT (I).  
 
All MEG recordings (I) were performed in the magnetically shielded room of the Low 
Temperature Laboratory, Helsinki University of Technology. Magnetic spontaneous brain 
activity (0.5-45 Hz) was recorded with a whole-scalp neuromagnetometer (Neuromag-122™, 
Neuromag Ltd., Finland; Ahonen et al., 1993), which  uses planar SQUID gradiometers 
coupling most strongly to the currents just below the recording site. We did not use a co-
registering technique with MRI. Instead, MRI (I) was used to exclude structural 
abnormalities of the brain. 
 
The 122 sensors of Neuromag-122™ are arranged in a helmet-shaped array, with two 
orthogonal sensors in each of the 61 measurement sites. Magnetic spontaneous cortical 
activity was measured for 4 min when the patient was relaxed with her eyes open and for 4 
min with her eyes closed. The exact location of the subject's head with respect to the sensors 
was determined by measuring the magnetic signals produced by small currents delivered to 
three coils attached to the scalp. The locations of the coils with respect to the nasion and 
periauricular points were obtained with a 3-D digitizer. Frequency spectra at each sensor 
were calculated from 4-min recordings of spontaneous magnetic activity during the eyes-open 
period by advancing a 3.4 s time window in 1.7 s steps and averaging the spectra (Figure 1). 
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The spectral values (in fT/cm vHz) before treatment were used as the baseline (100%), and 
the percentage from the baseline level was calculated both for the subregions and the LF/O 
and the RF/O at M4, at M8/9, and at MF. Changes in the MADRS score were calculated as a 
decrease (%) from the pretreatment level at M4 and M8/9.  
This thesis did not aim to study modulation of the spontaneous brain activity as measured by 
MEG. 
4.6. Statistical analyses 
In all studies, non-parametric tests were used if the variables were not normally distributed 
(Wilk-Shapiro-test). Other indications for non-parametric statistics are as follows: the values 
both for seizure threshold (II and III) and for the age-groups are more ordinal than 
continuous variables (III), the subgroup comparisons included small number of patients (III), 
and use of an estimate for the number of treatments (ENT) for patients who had markedly 
poor response to eight randomized ECT treatments and were therefore treated with the BT 
ECT (IV and V). 
Randomization (IV and V) was done by computer (Medstat, version 2.12) using a block 
randomization (six patients per block). Assignment was concealed until administration of the 
first ECT treatment. For study IV, the patients were randomized to RUL 5, RUL 2.5, and BF 
1. For Study V, after the patients were selected to Group 1 and Group 2, they were 
randomized to RUL 5, and RUL 2.5. 
 
The results (Tables) are expressed as medians [(means), minumum -maximum value)]. 
 
Analyses in Study IV were done among study completers. In study V, analyses were 
performed from the intent-to-treat (ITT) sample using the last-observation-carried-forward 
(LOCF) method. For this analysis, we included both study completers and non-completers 
who had received at least one ECT treatment after randomization. For five patients, post-ECT 
HDRS scores were not available. For these patients, the HDRS ratings and number of 
randomized treatments were as follows: HDRS 4, six; HDRS 4, eight; HDRS 4, twelve; pre-
ECT HDRS, one; pre-ECT HDRS, three. Regarding MMSE analysis, pre-ECT MMSE 
scores were not available for four patients. For three patients post-ECT MMSE scores were 
not available. The MMSE ratings and number of randomized treatments for these three 
patients were as follows: MMSE 4, eight; pre-ECT MMSE, three; MMSE 4, seven. As a 
sensitivity analysis, we also performed an analysis among study completers who had HDRS 
and MMSE ratings both prior and after the course of the randomized treatment. 
 
All tests were two-tailed, and the statistical significance level was set at α = 0.05. Statistical 
computations were performed with the BMDP New System (BMDP Statistical, Software, 
Inc, Los Angeles, California, 1994). Because of a lack of appropriate tests in the BMDP New 
System, we used for the confidence interval analysis the CIA (Software for Confidence 
Interval Analysis, BMJ 1989, London) (II), for the analysis of multiple comparisons of the 
Kruskal-Wallis test the BMDP Classic Release 7 (1993) (III and IV), for the comparison of 
nominal data with small cell frequencies Fisher-Freeman-Halton’s exact test the StatXact 
(Cytel Software corp., Cambridge, MA, 1999) (Study IV), and for the ANCOVA the SPSS 
for Windows 10.0 (SPSS Inc., Chicago, USA) (V). 
 
Two-group comparisons were made for nominal variables with Fisher’s Exact Test (II and 
V), and with Fisher-Freeman-Halton’s exact test (IV). For non-nominal variables, two-group 
comparisons were done with the two-tailed paired t-test (I), with the Mann-Whitney U test 
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(II, III, IV and V), with the independent sample t-test (V), and with the Analysis of 
covariance (ANCOVA)(V). Three-group comparisons were done with the Kruskall-Wallis 
test (III and IV). Correlations were done with simple linear regression (I) or with Spearman 
rank correlation (rs) (II and III). 
 
The main outcome measures of this thesis are shown in Table 6. 
 
Table 6. Outcome measures of studies I-V 
Outcome measure Number of the 
study 
ECT-induced change (%) in frontal and occipital MEG slow-wave activity I 
Relation between change in MEG slow-wave activity (%) and MADRS score (%) I 
Initial ST levels (mC) in RUL and BF ECT II & III 
Relation between seizure duration (s) and initial RUL ST and BF ST II 
Comparison between ECT dosing methods III 
    Age (year) / ST (mC) ratio at different RUL ST and BF ST levels  III 
    A fixed high dose (378 mC) / ST ratio at different RUL ST levels III 
Comparison of number of treatments (ENTs) between BF ECT 1, RUL ECT 2.5 
and RUL ECT 5 
IV 
Comparison of number of treatments (ENTs) between Group 1 and Group 2  V 
Comparison of HDRS change (%) and number of responders between BF ECT 1, 
RUL ECT 2.5 and RUL ECT 5  
IV 
Comparison of HDRS change (%) and number of responders between Group 1 and 
Group 2  
V 
Change of ECT treatment randomized  IV and V 
MMSE change (%) IV and V 
MMSE change negative IV and V 
Cognitive risk IV and V 
Cognitive risk and nonresponse IV and V 
  
 
The estimated number of treatment (ENT) was given a score of 14 (IV and V) because the 
maximal number of the randomized treatments was 13, determined on a clinical basis. 
Regarding the HDRS and MMSE ratings (IV and V), the scores prior to ECT treatment were 
used as the baseline values, and the percentage of change by the randomized treatments was 
calculated after the last treatment (HDRSL%, and MMSEL%, respectively). Patients were 
considered to have responded to treatment if they had scores of less than ten for their 
HRSDL ratings. Study V additionally provided that HDRSL% was at lest 60. On the other 
hand, the patients were considered to have a cognitive risk if they had any worsening in the 
MMSE total score, i.e., MMSEL% < 0.  The possibility of concomitant occurrences of 
cognitive risk (yes/no) and nonresponse (yes/no) were calculated for all patients. 
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5. RESULTS 
5.1. Patients and methods 
The clinical data for study patients are shown in Table 7. One Study II and III patient 
participated also in Study I. Four study II and III patients were treated again during the study 
period and participated then in Study IV (two patients) and in Study V (two patients). 
 
Table 7. The clinical characteristics of the study patients 
     
 Study I Study II and III Study IV Study V 
Number of patients N = 7 N = 80 N = 22 N = 40 
RUL ECT/BF ECT 4/3 50/30 15/7 40/0 
Age (years) 34.0 (35.1, 
24-46) 
48.0 (48.9, 24-77) 56.5 (56.0, 
39-68) 
52.0 (53.0, 
28-77) 
Sex (F/M)  6/1 53/27 13/9 25/15 
Previous ECT (yes/no) 0/7a 23/57b 9/13b 12/28b 
Psychotic features (yes/no) 2/5 18/62  4/18 5/35 
Unipolar/bipolar depression  7/0 71/9 17/5 34/6  
Duration of current episode (wk)c   23.0 (46.1, 5-
104) 
52.0 (54.3, 
8-104) 
MADRS (baseline) 31 (31.9, 22-
42) 
   
HDRS (baseline)   27.5 (27.2, 
16-40) 
24.0 (25.3, 
13.0-42.0) 
MMSE (baseline)   27.0 (26.3, 
19-30) 
27.0 (27.2, 
19-30) 
Pre-ECT EEG (normal/abnormal) 7/0 63/7   
Use of BZDs the day prior to ECT (yes/no)  58/22   
Use of BZDs during the course of ECT (yes/no) 6/1    
Dose of lorazepam-equivalent during the ECT course (mg)   0.8 (1.0, 0.0-
3.0) 
0.8 (1.1, 0-
3.0) 
Use of neuroleptic medication the day prior to ECT (yes/no)  49/31   
Use of neuroleptic medication during the ECT course (yes/no) 5/2    
Dose of chlorpromazine during the ECT course     27.6 (64.9, 
0.0-320.3) 
19.2 (60.3, 
0-320.3) 
Dose of chloralhydrate during the ECT course   1.1 (1.1, 0.0-
2.1) 
1.0 (1.0. 0-
2.1) 
Use of ADs the day prior to ECT (yes/no)  21/59d   
Use of ADs during the ECT course (yes/no) 3/4    
Number of AD trials during the current episode   2.0 (2.1, 1-6) 2.0 (2.2, 1-
7) 
Prior adequate AD treatments (yes/no)   17/5e 34/6 
     
a
refers to a six months period; 
b
refers to a three months period; 
c
an upper limit of 104 weeks was used. 
d
 14/16 for BF ECT and 7/43 
for RUL ECT, p  = 0.0032, 
e
the number of prior adequate antidepressant treatment trials was different between RUL ECT 5, RUL 
ECT 2.5 and BF ECT (8/0 vs. 6/1 vs. 3/4, p = 0.022. 
The patients (I-V) continued with their somatic medications prescribed prior to ECT. 
 
 
The clinical and treatment parameters (II and III) were similar for the RUL and BF ECT 
groups except for the use of AD medication the day prior to the first ECT treatment. The BF 
ECT patients were more often on AD medication; nine patients were on SSRIs (three RUL 
and six BF patients), eight patients were on TCAs (three RUL patients and five BF patients), 
one BF patient had a combination of SSRI and TCA, and three patients were on 
moclobemide (one RUL and two BF patients). The number of prior adequate antidepressant 
treatment trials was different between RUL ECT 5, RUL ECT 2.5 and BF ECT (IV). The 
Group 1 patients (V) tended to be older (t = 1.99, df = 38, P = 0.0539), had higher baseline 
HDRS scores (t = 2.74, df = 38, P = 0.0093), and lower baseline MMSE scores (P = 0.0053) 
than Group 2 patients.  
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Clinical and ECT data for Study I are shown in Table 8. 
 
Table 8. Clinical and ECT data of the ECT/MEG study (Study I) 
        
Patient 1 2 3 4 5 6 7 
Age (years) 28 41 46 34 24 44 29 
Sex (M/F) F F F F F F M 
Use of BZDs (yes/no) y y y y y n y 
Use of neuroleptics (yes/no) y y y n y n y 
Use of ADs (yes/no) n y y n y n n 
ECT stimulus placement RUL BF BF RUL BF RUL RUL 
Initial seizure threshold (mC) 50.4 50.4 50.4 25.2 50.4 50.4 25.2 
Charge (mC)a 204.4 82.8 81.0 114.8 53.2 219.0 100.8 
Motor seizure duration (s) a 45 50 50 47 54 47 44 
MADRS at M0 42 36 31 30 33 29 22 
MADRs at M4 33 23 20 13 26 19 12 
MADRS at M8/9  6 26 11 6 4 18 8 
 
       
a Averaged per treatment up to M8/9. 
        
 
Characteristics of treatment and seizure parameters for the first treatment session including 
the initial ST measurement (II and III) are shown in Table 9. 
 
Table 9. Treatment and seizure parameters at the first ECT treatment  
(Studies II & III) 
Atropine (mg) a 0.40 (0.42, 0.30-0.50) 
Methohexital (mg) / body weight (kg) a  0.82 (0.90, 0.61-1.64) 
Succinylcholine (mg) / body weight (kg) (N = 79) a, b 0.52 (0.57, 0.35 - 1.02) 
Initial ST (mC) level 50.4 (63.3, 25.2-151.2) 
 RUL ST level (n = 50) 50.4 (49.9, 25.2-75.6) 
 BF ST level (n = 30) 100.8 (85.7, 50.4-151.2) 
Number of subconvulsive stimuli (0/1/2/3) 21/48/11/0 
Static impedance (Ω)a, c 1605.0 (1507.6, 320.0-2440.0) 
Motor seizure duration (s) 53.0 (54.9, 30.0 - 95.0) 
EEG seizure duration (s) (N = 74)  64.5 (67.9, 28.0 - 138) 
Suppression index (N = 74)  82.5 (79.2, 30-97) 
 
Due to non-randomization of the patients to RUL and BF ECT, no statistical comparisons were made 
between any of the seizure or seizure threshold measure between the two stimulus electrode placements. 
aThe differences between RUL and BF ECT were not statistically significant.  
bOne patient was excluded because of use of mivacurium (0.07 mg/kg iv dose) as muscle r elaxant. 
cRefers to skin to electrode contact. 
  
 
Treatment and seizure parameters during ECT course (IV and V) are shown in Table 10. 
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Table 10. Treatment and seizure parameters during the course of the ECT 
treatment (Studies IV and V) 
 
        
 
 Study IV Study V 
 
 Whole 
sample 
RUL ECT 
5 
RUL ECT 2.5 BF ECT 1.0 Whole 
sample 
Group 1 Group 2 
RUL ECT 5 
          / 
RUL ECT 2.5 
  
8/7 
    
20/20 
 
8/8 
 
12/12 
         
RUL ECT 
        /  
BF ECT 
  
15/7 
    
40/0 
  
         
Initial ST level 
(mC) 
 50.4 (64.1, 25.2-
151.2) 
50.4 (53.5, 
50.4-75.6) 
50.4 (54.0, 
25.2-75.6) 
100.8 (86.4, 
50.4-151.2) 
50.4 (52.3, 
25.2-75.6) 
50.4 (55.1, 
25.2-75.6) 
50.4 (50.4, 
25.2-75.6)  
         
Charge (mC)  147.6 (185.6, 
75.6-378.0)  252.0
a
 (277.7, 
252.0-378.0) 
126.0 (146.1, 
75.6-241.2) 
120.4 (119.9, 
100.8-151.2) 
241.2 
(208.0, 
75.6-378.0)  
241.2 
(218.5, 75.6 
-378.0) 
191.5 
(200.6, 
75.6-
378.0)   
         
Duration of 
seizures, motor 
(s) 
 41.3 (41.5, 35.3-
48.0) 
38. 8 (40.1, 
35.3-46.0) 
43.6 (44.1, 
41.1-48.0) 
40.1 (40.7, 
36.0-47.4) 
43.2 (42.8, 
28.7-56.4)   
42.3 (41.1, 
28.7-48.0) 
43.5 (43.9, 
32.3-56.4) 
         
Duration of 
seizures, EEG 
(s) 
 51.3 (54.0, 37.3-
141.4) 
46.4 (58.6, 
38.3-141.4) 
55.9 (54.3, 
43.8-59.3) 
51.0 (48.4, 
37.3-56.8) 
50.8 (53.3, 
28.0-141.4) 
51.9 
(54.8,28.0-
141.3) 
50.4 (52.3, 
36.2-77.8) 
         
Subconvulsive 
treatments, no. 
patients 
  1
b
 
0 4    
         
Parameters except those for the intial seizure threshold refer to median (mean, minimum-maximum) values after the first treatment. 
a 
p = 0.0004 (252 vs. 126 vs.120.4). RUL ECT 5 > RUL ECT 2.5, and RUL ECT 5 > BF ECT 1.0, p < 0.05. 
b 
1/7 vs. 0/7 vs. 4/3, p = 0.044. 
         
 
5.2. Attrition 
Of the included 82 patients, two BF patients (II and III) were excluded. The first one (a 54 
year-old woman, P 1) had at the first subconvulsive stimulus a 20-s asystole which resolved 
spontaneously without complications. The patient was not restimulated. She had a history of 
hypertension treated with beta blockers, and prior to ECT, she had had doxepine withdrawal 
for six days. The second one (a 63 year-old woman, P 2) did not exhibit a clinical seizure of 
adequate duration even at the highest stimulation level.  
 
Two patients (P 1 and P 3) out of 24 (8%) could not complete the Study IV and were 
considered to be dropouts. P3 (RUL ECT 2.5) was excluded after seven ECT treatments 
because of ventricular extrasystole.  
 
Six out of 40 patients (15%)(V), one in Group 1 (P 3) (6%) and five (P4, P5, P 6, P 7 and P 
8) in Group 2 (21%) were non-completers. In Group 2, one RUL ECT 5 patient (P 4) had to 
discontinue the course of the treatment after three treatments because of regurgitation of 
gastric contents, one RUL ECT 2.5 patient (P 5) after the first treatment because of a 
hypomanic switch, two RUL ECT 5 patients (P 6 and 7) after three treatments because of 
high elevations of blood-pressure, and one RUL ECT 2.5 (P 8) patient after three treatments 
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due to alcohol abuse. The decision to discontinue ECT treatment was made by the patient in 
one case, by the anesthetist in four cases, and by the attending physician in one case.  
 
5.3. Neurophysiological aspects 
Study I. The ECT-induced MEG changes are shown in Table 11. In LF, the ECT treatment 
did not induce any statistically significant MEG changes. 
 
Table 11. The ECT-induced MEG slow-wave change (%) 
    
 M4 M8/9 MF 
LF NS NS NS 
RF NS theta range: 141.2 (179.7, 119.7-276.4) 
p = 0.018 
NS 
O theta range: 129.3 (142.9, 84.0-210.6) 
p = 0.040 
delta range: 130.7 (129.7, 89.7-163.8) 
p = 0.021 
theta range: 165.1 (206.8, 85.2-423.4) 
p = 0.042 
NS 
LF/O NS NS NS 
RF/O NS NS NS 
 
   
NS, non significant, p > 0.05. 
M4 refers to time period 24 to 48 hours after the fourth ECT, M8/9 refers to the same time period 
after eight or nine treatments, and MF refers to the measurement after a one-month follow-up 
period. 
    
 
Patient 4, displayed in Figure 3, showed the most prominent change after nine treatments in 
her theta activity in the LF (382%) and RF (276%) subregions. The change in O was 213%.  
 
The increase was more prominent in the theta than in the delta band both at M4 (131.6 ± 
44.4% vs 114.1 ± 40.1%, p = 0.019) and at M8/9 (179.7 ± 65.5% vs 130.7 ± 64.3%, p = 
0.026) in RF. In other comparisons at M4, at M8/9, or at MF, there were no statistically 
significant differences between changes in theta and delta activities.
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The age of patients tended to increase in relation to their ST levels both in the RUL ECT 
group (p = 0.081, Kruskal-Wallis test), and in the BF ECT group ( p = 0.060) (Table 13). 
The age/ST ratio decreased relative to the ST level both in the RUL ECT group (p < 0.0001, 
Kruskal-Wallis test), and in the BF ECT group (p = 0.0005). Using multiple comparison for 
the Kruskal-Wallis test, the age/ST at the lowest ST level was higher than that at the second 
or third level both in the RUL ECT and in the BF ECT group. The age/ST at the second level 
was not different from the age/ST at the third level in the RUL ECT group, or in the BF ECT 
group. The FHDM/ST ratio was ≥ 5 in the RUL ECT group at all ST levels the highest level 
being 15 (Table 13). 
 
Table 13. The relation of age-base dose and fixed high dose to the initial seizure threshold (ST) 
 Age (y) Age/ST HAM/ST AM/ST FHDM/ST ratio 
ST (mC) Median Range Median Range Median Range Median Range  
RUL ECT 48.5 28-69        
25.2 46 29-61 1.8 a 1.2-2.4 4.4 a 2.9-6.1 9.0 a 6.0-12.0 15.0 
50.4 48 28-68 1.0 0.6-1.4 2.5 1.4-3.4 5.0 3.0-7.0 7.5 
75.6 57.5 44-69 0.8 0.6-0.9 1.9 1.5-2.3 4.0 3.0-4.5 5.0 
BF ECT 47.0 24-77        
50.4 41.5 24-63 0.8 b 0.5-1.3 2.1 b 1.2-3.1 4.1 b 2.5-6.5  
100.8 46 32-77 0.5 0.3-0.8 1.1 0.8-1.9 2.3 1.5-4.0  
151.2 66 57-68 0.4 0.4-0.5 1.1 0.9-1.1 2.2 2.0-2.5  
          
FHDM, fixed high dose method: ECT dose = 378.0 mC; 
a
 p < 0.0001; 
b
 p = 0.0005. 
          
 
The age/ST ratio by gender was different relative to the ST level both in the RUL ECT group 
(for men, 1.5, 0.9, and 0.8, p = 0.034; for women, 1.8, 1.0, and 0.6, p = 0.0002, Kruskal-
Wallis test), and in the BF ECT group (for men, 1.3, 0.4, and 0.4, p = 0.043; for women, 0.7, 
0.5, and 0.4, p = 0.026) (study III). Using multiple comparison for the Kruskal-Wallis test, 
both men and women in the RUL ECT group had a higher age/ST ratio at the first level 
stimulation level than at the third level. The ratio at the first level for women was higher than 
at the second level. In the BF ECT group, the comparisons between subgroups were not 
statistically significant. 
 
In the Study III, the seizure threshold by age was found to be different for men in the RUL 
ECT group (p = 0.0089, Kruskal-Wallis test) and for the women in the BF ECT group (p = 
0.0078) (Table 14). Using multiple comparison for the Kruskal-Wallis test, the seizure 
threshold (BF ECT group) for women in the youngest age group was lower than that in the 
oldest age group. The comparison between other subgroups was not statistically significant. 
 
Table 14. Median (range) initial seizure threshold (mC) by age and gender 
 RUL ECT BF ECT 
Age (y) Male Female Male Female 
10-29 25.2 a 50.4 (50.4-50.4) 100.8 50.4 (50.4-50.4) b 
 N = 1 N = 2 N = 1 N = 4 
30-59 50.4 (25.2-75.6) 50.4 (25.2-75.6) 100.8 (50.4-151.2) 100.8 (50.4-100.8) 
 N = 12 N = 23 N = 8 N = 12 
60-85 75.6 (75.6 - 75.6) 50.4 (25.2-50.4) 50.4 126.0 (100.8-151.2) 
 N = 4 N = 8 N = 1 N = 4 
     
a
 p = 0.0089, b p = 0.0078. 
     
 
In the RUL ECT group (III), the patients on neuroleptics had a lower ST level (median  50.4, 
mean 46.2) than those without the medication (median 50.4, mean 55.4, p = 0.031, Mann-
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Whitney U test). In the BF ECT group, the patients on benzodiazepines had a higher ST level 
(median 100.8 mC, mean 92.0) than those not using benzodiazepines (median 50.4, mean 
64.8 mC, p = 0.05). Other calculations regarding ST by psychotropic medication were 
statistically non-significant.  
 
Even though more patients responded to the high dose RUL treatment than to moderate dose 
RUL or BF treatments, the treatment groups were not statistically different (number of 
responders/nonresponders between RUL ECT 5, RUL ECT 2.5, and BF ECT 1.0: 7/1 vs. 3/4 
vs. 3/4, p = 0.12; median/mean change in the HDRS scores: 72.9% / 70.5% vs. 59.5% / 
57.8% vs. 64.3% / 44.8%, p = 0.30, respectively) (IV). Patients treated with BF ECT 1.0 
received more treatments than patients treated with RUL ECT 5 (12 vs. 7, p < 0.05). The 
change of the MMSE scores or the likelihood of the occurrence of a simultaneous cognitive 
risk and nonresponse did not differ between the ECT techniques (Table 15).  
 
Table 15. Clinical outcome of studies IV and V 
 
 Study IV Study V 
 Whole 
sample 
RUL ECT 5 RUL ECT 2.5 BF ECT 1.0 Whole 
sample 
Group 1 Group 2 
HDRS 
(baseline) 
27.5 (27.2, 
16-40) 
29.0 (29.1, 
20-40) 
27.0 (27.9, 22-
37) 
27.0 (24.4, 
16-29) 
 24.0 (25.3, 
13-42)a 
 29.0 (28.6, 20-
40)    
 23.0 (23.0, 13-42) 
HDRS, after 
last ECT 
9.0 (10.6, 3-
22) 
8.0 (8.4, 3-
19) 
15.0 (12.0, 5-
22) 
10.0 (11.9,5-
21) 
13.0 (12.9, 
3-27) 
9 (10.2, 3-27) 13 (14.6, 8-27) 
HDRS 
change (%) 
68.9 (58.3, 
−31-88) 
72.9 (70.5, 
35-88) 
59.5 (57.8, 27-
82) 
64.3 (44.8, 
−31-82) 
 47.9 (45.6, 
−5.6-87.5)b 
68.9 (64.3, 
26.7-87.5) 
34.5 (33.1, −5.6-70.0) 
        
Responders 
(yes/no) 
13/9 7/1 3/4 3/4 12/28c 10/6 2/22 
        
Change of 
ECT 
treatment 
randomized 
(yes/no) 
 
 
3/19 
 
 
0/8 
 
 
1/6 
 
 
2/5 
 
 
3/37 
 
 
1/15 
 
 
2/22 
        
Number of 
treatments, 
ENT 
8.0 (9.2, 4-
14)d 
7.0 (7.3, 4-
12) 
8.0 (9.6, 7-14) 12 (11.0, 6-
14) 
 8.0 (7.7, 1-
14) 
7.5 (8.3, 4-14) 8.0 (7.4, 1-14) 
        
MMSE 
baseline 
27.0 (26.3, 
19-30) 
25.5 (25.0, 
19-29) 
27.0 (27.0, 26-
29) 
27.0 (27.0, 
24-30) 
27.0 (27.2, 
19-30) 
27.0 (26.0, 19-
29) 
28.5 ( 28.1, 25-30) 
MMSE after 
last 
treatment 
26.5 (26.5, 
20-30) 
25.0 (25.9, 
22-30) 
28.0 (27.3, 23-
30) 
26.0 (26.6, 
20-30) 
27.5 (26.6, 
21-30) 
27.5 ( 26.6, 22-
30) 
27.5 (26.6, 21-30) 
MMSEL%  0.0 (1.2, 
−16.7-26.0 
2.4 (4.0,−12-
26)  
0.0 (1.1, −12-
15) 
0.0 (−1.9, 
−17-7)  
−1.5 (−1.8, 
−22.2-26.0)e 
1.9 (2.7, 
−12.2-26.0) 
−3.2 (−5.3, −22.2-4.0) 
Cognitive 
risk (yes/no) 
8/14 4/4 2/5 2/5 18/18 6/10 12/8 
Cognitive 
risk and 
nonresponse 
(yes/no) 
1/21 0/8 1/6 0/7 11/25 f 1/15 10/10 
        
a 
p = 0.0093, b p < 0.0001, c p = 0.0004, d p = 0.033, e p = 0.016,  f p = 0.0091. 
Positive values on percentage change indicate a better cognitive functioning as compared with the baseline. Cognitive risk = MMSE 
change < 0%, nonresponse = HDRS scores after last ECT ≥ 10, and in addition (Study V), the improvement in HDRS scores at least 
60%. 
        
 
  51 
The number of responders vs. nonresponders was higher in Group 1 than in Group 2 both in 
the ITT analysis (10/6 vs. 2/22, P = 0.0004, Table 3) and among study completers (10/5 vs. 
2/14, P = 0.0032) (Table 15) (V). 
 
The improvement in HDRS score was higher in Group 1 than in Group 2 both in the ITT 
analysis and among study completers (64.3% vs. 33.1%, t = 4.56, df = 38, P = <0.0001; 
64.6% vs. 35.9%, t = 3.71, df = 29, P=0.0009, respectively). Using ANCOVA with pre-ECT 
HDRS scores as a covariate, the difference was statistically significantly different in the ITT 
sample (P = 0.0016), and among study completers (P = 0.0076), and remained statistically 
significantly different when both the pre-ECT HDRS scores and age were used as covariates 
both in the ITT sample (P = 0.0036, Table), and among study completers (P = 0.0152). 
 
Three patients received a course of BT treatment due to a markedly poor response to the 
randomized RUL ECT treatment. The number of BT patients was not statistically 
significantly different between Group 1 and Group 2 (1/15 vs. 2/22, P = 1.0). 
 
The number of treatments was not different between Group 1 and Group 2 in the ITT sample 
(Table ) or among study completers (median, mean, range: 8.0, 8.3, 4-14 vs. 8.0, 8.8, 4-14, P 
= 0.5844).  
 
The mean MMSE scores improved in the Group 1 patients in contrast to impairment in the 
Group 2 patients both in the ITT sample and among the study-completers (2.7% vs. -5.3%, t 
= -2.53, df = 34, P = 0.0159; 2.6% vs. -6.9%, t = -2.52, df = 27, P = 0.0178, respectively). 
Using ANCOVA with pre-ECT MMSE scores as a covariate, the difference did not remain 
statistically different in the ITT sample (P = 0.2518), and among study completers (P = 
0.2333). The difference was non-significant also with pre-ECT MMSE scores and age as 
covariates in the ITT sample (P = 0.1803), and among study completers (P=0.0961). 
 
The likelihood of the occurrence of a simultaneous cognitive risk and non-response was 
significantly higher for Group 2 than for Group 1 in the ITT sample (10/10 vs. 1/15, P = 
0.0091, Table 15) and among the study completers (8/6 vs. 1/14, P = 0.0052). 
 
The ten patients in Group 2 who had simultaneous cognitive risk and non-response were 
included in Group 2 because of their mild major depressive episode (n = 4), because of their 
history of previous non-affective psychosis (n = 2), because of alcohol abuse (n = 2), and 
because of severe medical illness (n = 2). Nine of them had had adequate antidepressant 
treatments during the current major depressive episode. 
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6. DISCUSSION 
In this thesis, I have been able to demonstrate a relationship between MEG slow-wave 
activity and clinical outcome of ECT, an inverse relationship between seizure duration and 
initial ST level in RUL ECT but not in BF ECT, the individual value of using a DTM in RUL 
and BF ECT, a faster response to high-dose RUL ECT than low-dose BF ECT, and a lower 
RUL ECT response in a heterogeneous depression goup as compared to that in a 
homogenous group of patients with major depressive episodes. 
. 
6.1. Sample 
All the study patients had been hospitalized because of depression. The severity of the 
episode ranged from mild to severe. Twenty-three percentage of the patients had depression 
with psychotic features. This is in agreement with the previous studies showing a range from 
16% up to 54% for psychotic depression in clinical practice (Dubosky and Thomas, 1992). 
All the study patients participating in the clinical studies (IV and V) had had at least one 
treatment with AD medication (Table 7). The sample of depressive patients in this thesis was 
made more representative than the previous ECT efficacy studies (Bailine et al., 2000; 
McCall et al., 2000a; Sackeim et al., 2000a) by including the comorbid patient group and 
also patients with mild major depressive episodes. Recent efficacy studies have made the 
analyses using study completers. In addition to this method, an ITT-analysis was carried out 
in Study V. The differences between the outcomes of these two methods were however 
small. 
6.2. Limitations and confounding factors 
The small sample size is a clear limitation of the MEG study. However, I assume that a 
relative low modulation of MEG signal may explain the finding that a relationship between 
clinical outcome and MEG changes was found after four treatments but no longer after eight 
or nine treatments. Regarding the finding on the prefrontally accentuated EEG slow-wave 
activity in ECT responders (Sackeim et al., 1996), the effect of the applied methods, the 
spatial origin, the mechanism of the induced slow-wave activity and the functional 
significance of the ECT induced EEG activity has been challenged (Volavka and Czobor, 
1996). Although the EEG and the MEG methods are different, the questions raised by 
Volavka and Czobor concern MEG as well. 
 
The interactions between ECT and psychotropics in cerebral physiological and clinical 
effects are not well known. The patients in the MEG study continued the medications they 
had used prior to their ECT treatments to eliminate the withdrawal effects of the medication 
on the MEG signal. In the clinical Studies (IV and V), the AD medication was discontinued 
before ECT but patients were allowed to use lorazepam, chlorpromazine and/or 
chloralhydrate (Table 7). Concomitant use of BZDs and ECT may lessen the efficacy of 
treatment in depression (Greenberg and Pettinati 1993). In the clinical Studies (IV and V), 
the doses of lorazepam were at the same level as in the efficacy studies of Sackeim et al. 
(1993 and 2000a). At present, there is little known about the combined clinical effects of 
both antipsychotic agents and ADs and ECT (Klapheke, 1993; Pritchett et al., 1993; see 
APA, 2001).  
 
Due to non-randomization and different titration schedules, I did not carry out any statistical 
comparisons between RUL and BF seizure measures in the Studies II and III. The non-
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randomization might have caused a selection bias towards the two ECT groups because many 
factors affect ST level (Table 2). The RUL and BF ECT groups were, however, different 
only in respect to the use of ADs (Table 7). The BF ECT patients were more often on AD 
medication. Nine patients were on SSRIs (three RUL and six BF patients), eight patients 
were on TCAs (three RUL patients and five BF patients), one BF patient had a combination 
of SSRI and TCA, and three patients were on moclobemide (one RUL and two BF patients). 
TCAs may lower the ST level (Warrington, 1992) whereas SSRIs have been found to have 
no effect on the ST level (Boyer and Feighner, 1992). On the other hand, SSRIs have been 
found to increase the ST of rats (Watanabe et al., 1998). Thus, the effect of ADs on our 
findings can not be excluded. The use of neuroleptics has been found to be associated with a 
lower ECT ST level (Coffey et al., 1995a). In our RUL and BF groups, the number of 
patients on neuroleptics between the two groups was not different. Regarding BZDs, a mean 
average lorazepam dose of 0.85 mg in the 48 hours prior to ECT has not been found to be 
associated with the initial ST level (Boylan et al., 2000). Our approximate median dose 
equivalents for lorazepam in the 24 hours prior to ECT were 1.0 mg both for the RUL and 
BF groups. However, the clinical equivalent doses of BZDs may not be the same as the 
equivalent doses regarding their effects on ST. Furthermore, different inter-electrode 
distances between RUL and BF ECT and regional differences in the thickness of the skull 
may have been other confounding factors (Sackeim et al., 1994). 
 
Cognitive side-effects of RUL or BF ECT may not be optimally detected with the MMSE 
alone (Calev et al., 1995; see Abrams, 1997; Austin et al., 2001). The MMSE grossly 
assesses global cognitive status, and not the central cognitive effects of ECT, particularly 
retrograde amnesia. Furthermore, more specific measures of executive functioning and 
parietal lobe functioning would be necessary to evaluate fully the cognitive side-effects of BF 
and RUL ECT, respectively. Unfortunately, specific recommendation regarding an optimal 
instrument to evaluate the cognitive side-effects of ECT is not available (see APA, 2001). 
However, the impact of ECT on cognition, particularly orientation and memory, should be 
assessed in terms of both objective findings and patient report prior, during, and after the 
ECT course. 
6.3. Mechanism of action of ECT 
Dysfunction in the frontal cortical-subcortical circuits has been found to be associated with 
mood disorders (Mayberg, 1997; Soares and Mann, 1997; Strakowski et al., 2000). 
According to Mayberg (1997), concurrent inhibition of the overactive paralimbic regions and 
normalization of hypofunctioning dorsal cortical areas are necessary for disease remission, 
whether facilitated by psychotherapy, medication or ECT. ECT has been shown to induce 
accentuation of the interictal EEG slow-wave activity in the frontal cortex. This change has 
been found to have a relation to clinical outcome of ECT treatment (Roth, 1952; Fink and 
Kahn, 1957; Sackeim et al., 1996). Therefore, the MEG study (I) focused on this specific 
ECT-induced neurophysiological change in the brain function. 
 
Sackeim et al. (1996) have found that the efficacy of ECT was linked to the induction of 
delta band of the EEG slow-wave activity in the prefrontal cortex (topographic pattern 1). 
This pattern revealed the ECT-responders among non-responders. In the present MEG study, 
the increase in the postconvulsive left frontal MEG activity in the theta band correlated with 
the efficacy of the ECT treatment after four treatments (Figure 4) although the induced mean 
activity was not significantly increased. The relationship between MEG change and efficacy 
was significant also as measured by the left frontal to occipital (LF/O) and right frontal to 
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occipital (RF/O) changes in the MEG activity. The bilateral MEG findings showing the 
frontal accentuation of induced MEG activity (I) are in agreement with the topographic 
pattern 1 (Sackeim et al., 1996). The relation between efficacy of ECT treatment and increase 
in postconvulsive frontal slowing as measured both by EEG (Sackeim et al., 1996) and by 
MEG (I) were not dependent either on the electrode placement or on the stimulus dose. The 
changes in the EEG slow-wave activity have been previously shown to vary with the method 
of seizure induction, and with the number of seizures administered. In contrast, both the 
QEEG measure (Sackeim et al., 1996) and the MEG measures (I) may be more constant 
markers for efficient ECT treatments and clearly merit further studies. 
 
The present MEG study found outcome-related changes both in the left frontal cortex and in 
left and right frontal cortex as measured by LF/O and RF/O ratio. The role of the left frontal 
cortex particularly has been empasized by some studies in the pathogenesis of depressive 
disorders (George et al., 1994; George et al., 1995; Pascual-Leone et al., 1996). Direct 
stimulation of left prefrontal cortex by rapid-rate TMS, the treatment given without 
anesthesia, has been found to be beneficial in some depressive patients (George et al., 1995; 
Pascual-Leone et al., 1996). In major depression, cerebral asymmetry (alpha suppression) as 
measured by EEG has been found to occur so that there is less left frontal activation and 
greater right frontal activation (Davidson, 1992). On the other, Bruder et al. (1997) have 
found that the lateralization of EEG activation in depressed patients is dependent on the 
comorbid anxiety disorder. Using MEG, Reite et al. (1999) have found altered cerebral 
lateralization being associated with psychoses of schizoaffective disorder and bipolar I 
disorder. A lower activity on the left than right hemisphere has been found in patients with 
major depression also with TMS measurements (Maeda et al., 2000). However, Mayberg et 
al. (1999) have found that recovery from depression involves especially the right frontal 
cortex. Moreover, in the most recent TMS treatment study it was found that TMS given over 
right prefrontal cortex of depressive patients is beneficial (Klein et al., 1999). The recent 
ECT studies have not found a relationship between lateralized EEG changes and ECT 
efficacy (Weiner et al., 1986; Abrams et al., 1992; Sackeim et al., 1996). Thus, the 
relationship between the left hemispheric accentuation of the ECT-induced MEG changes 
and clinical outcome (I) clearly needs further studies. 
 
The MEG study (I) showed a change both in theta and delta frequency bands. The change in 
postconvulsive MEG theta activity correlated with the clinical outcome whereas in the 
EEG/ECT studies (Roth, 1952; Fink and Kahn, 1957; Sackeim et al., 1996), the clinical 
outcome has been found to correlate with the EEG delta activity. This difference might be 
explained by different dose-dependent effects of ECT on thalamic pacemakers based on the 
facts that thalamic pacemakers modulate the cortical rhythms of the brain (Steriade et al., 
1990), ECT affects thalamus (Diehle et al., 1994) and ECT induces neurohormone responses 
in a dose-dependend manner (Zis et al., 1993; Devanand et al., 1998; Lisanby et al., 1998). 
Delta activity has been found to be induced by higher mean stimulus intensities, i.e. by doses 
from 140mC to 318 mC (Sackeim et al., 1996) whereas theta activity has been shown to 
appear using lower intensities, i.e. by the doses of 95 mC (Sackeim et al., 1996) and by the 
mean dose of 122 mC in the present MEG study.  
 
The MEG findings in individual patients (Figure 3) might support at least partly a theory 
assuming that the spatial distribution of reduced functional activity following ECT is largely 
determined by the topography of seizure onset and that the reduction of functional activity in 
anterior frontal regions is critical to the ECT efficacy (Sackeim, 1994; Sackeim et al., 1996). 
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Sackeim has suggested that the exceeding of the individual ST in frontal lobes is the key 
factor to the efficacy of ECT. In the present MEG study, the high-dose RUL ECT treatment 
induced the most prominent change of the anteroposterior gradient and best recovery from 
depression of the patient number 4. This finding may indicate, that the dose of RUL ECT 
stimulus had reached the level where the anterior frontal tissue participates in seizure 
initiation. Low dose RUL ECT seizures may in general originate in perirolandic (motor strip) 
regions which have the lowest seizure threshold in the brain (Sackeim et al., 1994; Sackeim, 
1994). The low-dose BF ECT treatment (I) was relatively inefficient in inducing an increase 
in frontal slow-wave activity although the stimulus electrodes were placed frontally. Thus, 
the low-dose BF ECT may have been able to initiate seizures mainly in perirolandic region.  
 
The excellent temporal and reasonable spatial resolution and the possibility to directly study 
signals from different brain subregions and make comparisons between them are clear 
advantages for the MEG recordings. Co-registering techniques which are capable to detect 
ECT-induced changes accurately also in deep brain structures may be of special value in the 
future. [123I] ADAM with SPECT seems to have such a capacity (Kauppinen et al., 2002). 
Therefore, our research group is going to start an ECT study combining neurophysiological 
and SPECT methods to further test the neuroanatomical model of depression by Mayberg 
(1997). Although speculative, I consider that both the topography of seizure onset and the 
dose-dependent effects of ECT on thalamic pacemakers are essential in the mechanism of 
action of ECT. 
 
6.4. Initial RUL and BF ST levels 
The first ECT treatment given to a human patient included measurement of his individual ST 
level (Kalinowsky, 1986). Since then, the knowledge concerning ST measurement has been 
increased essentially. The individual ST is not absolute but is effected by many factors as 
indicated in Table 2. Therefore, the technical factors of the ECT treatment affecting ST level 
(I-V) were standardized to the maximum level. Regarding clinical factors, the control over 
confounding factors is more difficult. 
 
The initial ST of the RUL ECT has shown to vary in the range from 25mC to 300 mC 
(Sackeim et al., 1991). In this thesis, the range was from 25.2 mC to 75.6 mC. All ST 
measurements (II and III) were carried out at the first treatment session in contrast to the 
study of Sackeim et al. (1991). In general, the ST level increases individually during the 
course of the treatment (Sackeim, 1999). In consider, that that fact explains the difference in 
variance to a great extent. The protocol for ST measurement (II and III) was the same for 
both women and men, and the doses at the three first stimulus levels were identical to those 
of McCall et al. (1993a), and Rasmussen et al. (1994). However, both McCall et al. and 
Rasmussen et al. used a shorter interval (20 sec. vs. 30 sec.) between subconvulsive stimuli 
than the Studies II and III, and additionally, Rasmussen used a shorter stimulus pulse width 
(0.5 ms vs. 1.0 ms). The RUL ST level (II and III) is however quite similar to the low values 
among studies using brief-pulse stimuli and the d’Elia stimulus placement (Malitz et al., 
1986; Sackeim et al., 1987a; McCall et al., 1993b; Sackeim et al., 1993; Rasmussen et al., 
1994; Coffey et al., 1995a; Enns and Karvelas, 1995). 
 
The starting BF stimulus dose (50.4 mC) was adjusted at a clearly lower level than that (~115 
mC) used previously by Letemendia et al. (1993). In spite of this, 40% (12/30, 3 men and 9 
women) of BF patients seized surprisingly already for the first stimulus. Thus, a lower 
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starting dose, e.g. 25.2 mC, especially for women may be sufficient for BF ECT if a 
Thymatron machine with similar stimulus parameters (Table 4) is used as in this thesis. If the 
initial BF ST level really would be lower, the seizures might be longer, and might have an 
inverse relationship to the stimulus dose in a similar manner as that found in previous studies 
using RUL and BT ECT (Sackeim et al., 1987c; Sackeim et al., 1991; Coffey et al., 1995a). 
Also the efficacy of such a low-dose BF stimulus might be lower than that been found 
previously (Letemendia et al., 1993). 
 
Apart from finding patients with low STs, the DTM is useful in detecting patients with 
exceptionally high STs also in BF ECT. One of our BF ECT patients had an exceptionally 
high ST, i.e. higher than 201.6 mC. Patients with markedly high ST levels have been found to 
be rare (Krystal et al., 2000) if the confounding factors have been minimized.  
 
6.5. Relation between ST and seizure duration 
The Study II found an inverse relationship between the duration of seizures and the initial ST 
level in seizures after RUL stimuli just like in the previous studies (Sackeim et al., 1987c; 
Sackeim et al., 1991; Coffey et al., 1995a) (Table 12). The inverse relationship after RUL 
stimuli (II) could be found both in the analysis of motor and EEG data. However, no 
relationship was found after BF stimuli. The correlation was so poor (rs  = - 0.05 for motor 
seizures and rs = 0.06 for EEG seizures) that it could not be due to insufficient statistical 
power. The lack of an inverse relationship may indicate that we have overestimated the first 
level of the BF schedule. Both for RUL and BT ECT, where the stimulus is given over the 
temporal lobes, a higher initial stimulus dose induces a shorter seizure. Given this relation, it 
has been suggested that the measurement of RUL and BT ST assesses more than individual 
or treatment condition differences in the degree to which current is shunted away from the 
brain. ST measurement has been suggested to incorporate assessment of one or more 
dimensions that reflect endogenous neural processes that determine seizure duration 
(Sackeim et al., 1987c). Thus, future studies using a lower initial BF ST may show whether 
the biological counterparts for the RUL and BF STs really are different.  
 
6.6. Outcome: impact of ECT dose and characteristics of patients 
An active treatment of depression should result in remission instead of resulting in response 
(see APA, 2000). This aim was best fulfilled using the high-dose RUL ECT in patients with 
pure major depressive episodes (Table 15, IV) and worst in the heterogeneous depression 
goup (Table 15, V, Group 2). The response rates were 88% and 8%, respectively. The 
proportion of patients with major depressive disorder who have responded to ECT in the 
recent ECT studies has been found to range from 17% up to 87% (Sackeim et al., 1993; 
McCall et al., 2000a; Ng et al., 2000; Sackeim et al., 2000a; Petrides et al., 2001). The 17% 
response rate (Sackeim et al., 1993) was achiewed using the ‘just above ST level’ RUL ECT 
treatment whereas the 87% response rate was achiewed using the BT ECT dosed at 50% 
above ST level (Petrides et al., 2001). The abysmal response rate of the patients in the Study 
V is lower although the RUL stimuli (V) were higher than in the study of Sackeim et al. 
(1993). Thus, the outcome of RUL ECT treatment is dependent both on the ECT dose and on 
the characteristics of the patients. 
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6.7. Value of the ST measurement  
The latest report of APA (2001) suggests that the dosing range for RUL ECT stimulus should 
be from 2.5 to 6 times the ST level. This recommendation is mainly based on the studies of 
Sackeim and coworkers (1993 and 2000a). In the later study, Sackeim et al. have found that 
the best cognitive risk/benefit ratio as compared with other ECT techniques was achiewed 
when the RUL ECT treatment was dosed at 6x ST level. The DTM allows to give for the 
second treatment an exact dose relative to the initial ST level. However, all ECT reseachers 
do not support the use of the DTM but prefer to methods based on the predetermined doses 
(see Abrams, 1997). In the present study, both the age method and the fixed high dose 
method would have guided to give effective RUL ECT treatment to all the patients (Table 
13). The stimulus dosed at 5 times the ST level would have led us to give to the study II and 
III patients a stimulus dose which would have been less than the fixed high doses, i.e. 378 
mC and 403 mC, used previously (Abrams et al., 1991 and McCall et al., 2000a, 
respectively). 
 
The patients both in the RUL ECT and BF ECT groups with low STs would have received 
higher doses in relation to the initial ST than other patients if the age based dosing or the 
FHDM (only RUL ECT) had been used. Only a moderate correlation between age and 
seizure threshold was found in the RUL ECT group as in the previous studies (Sackeim et 
al., 1987a; McCall et al., 1993a; Beale et al., 1994; Coffey et al., 1995a; Enns and Karvelas, 
1995). The correlation between age and seizure threshold in the BF ECT group was even 
poorer. In the RUL ECT group the relation between seizure threshold and age was stronger in 
men than in women (Table 14). This finding is in agreement with those of Dykes and Scott 
(1998), and Sackeim et al. (1991). 
 
In the patients with the lowest STs (25.2 mC) the doses based on the AM and the FHDM 
would have been very high. Such doses have been found to impaire global cognitive 
functioning more than the benefit of the treatment (McCall et al., 2000a). Furthermore, the 
doses would have been even underestimated in these patients because ‘their true ST’ was 
either at the measured level or somewhere below it. The number of patients who had an 
adequate seizure at the first stimulus level (18%) is in agreement with the finding (15%) of 
the Columbia University group (Sackeim et al., 1987a).  
 
According to Letemendia et al. (1993), BF ECT is safe and effective when dosed just above 
the individual ST level. The HAM would have guided us to give nearly the dose 
recommended by Letemendia et al. (1993) to patients with moderate (100.8 mC) to high STs 
(151.2 mC). In patients with low STs (50.4 mC), both the HAM and the AM would have 
given significantly higher doses. The clinical meaning of this speculation may, however, be 
of little value because Letemendia et al. (1993) did not use any DTM in their dosing 
analyses. Thus, it is not clear that the BF ECT doses in the study of Letemendia et al. (1993) 
were ‘just above ST level’. In contrast, their BF ECT doses might have been at a clearly 
higher level relative to the intial ST level. The lack of the inverse relationship between the 
seizure duration and initial BF ST level in the study II and the relatively slow response 
induced by the low-dose BF ECT in the study IV (Table 15) support the possibility that the 
initial BF ST level may be at a lower level than has been suggested previously. 
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6.8. Comparison between RUL and BF ECT 
The high dose (5x ST level) RUL ECT had a good short-term antidepressant effect in 
patients with major depression (IV). This finding is in agreement with the results of recent 
RUL ECT studies (McCall et al., 2000a; Sackeim et al., 2000a). The response rate (88%) 
was nearly identical to that of 87% in the recent BT ECT study (Petrides et al., 2001). The 
high-dose RUL-ECT had a faster antidepressant effect than the low-dose BF ECT. Moreover, 
the higher response rate with high-dose RUL ECT compared to either moderate dose RUL or 
low-dose BF ECT is clinically significant. All the patients treated with high-dose RUL ECT 
had had an adequate antidepressant trial during the current major depressive episode, 
whereas only three of seven BF ECT patients did. Prudic et al. (1996) have found that 
patients who previously had failed one or more adequate AD medication trials are less likely 
to respond to subsequent ECT than patients not to known to be medication resistant. Thus, all 
Study IV findings suggest the superiority of high-dose RUL ECT over low-dose BF ECT.  
 
The low-dose BF ECT had a more gradual effect on the depressive symptoms of the patients 
than high-dose RUL ECT treatment (IV). The slow BF response may only be secondary to 
the fact that “just above threshold” BF but moderate and high dose RUL ECT were used. 
Moreover, the mean HDRS percentage improvement scores of BF ECT (IV) were lower than 
those of the BF ECT in the studies of Letemendia et al. (1993) and Bailine et al. (2000) (45% 
vs. 74% and 77%, respectively). All BF patients (N = 24) in the study of Bailine et al. (2000) 
reached remission by a mean of six ECT treatments, whereas only three out of seven of our 
BF ECT patients achieved remission using similar criteria. The relatively poor outcome of 
the BF ECT (IV) is at least partly due to the mean low stimulus level (120 mC) as compared 
with that (164 mC) in the study of Letemendia et al. (1993). In addition, four out of seven of 
our BF patients needed restimulations due to inadequate seizures during the ECT treatment 
course. This finding indicates that at least some of the treatments have been given with too 
small stimulus doses. 
6.9. Outcome of RUL ECT in depression 
The Study V shows that the patients with low severity of a major depressive episode or with 
a variety of somatic or psychiatric comorbidities (Group 2) have a significantly lower 
response rate to RUL ECT (8%) than patients with a pure, moderate to severe major 
depressive episode (63%). The Group 2 included those patients who have been excluded 
from the recent efficacy studies (McCall et al., 2000a; Sackeim et al., 2000a). The abysmal 
response rate in Group 2 is based upon quite strict response criteria, i.e., a decrease of at least 
60% in HDRS scores from baseline and a post-ECT score less than ten. For comparison, the 
mean percentage improvement in HDRS was 33% in Group 2 as compared with 64% in 
Group 1. This difference is also both clinically and statistically significant.  
 
Why did the two depression groups have such different antidepressant responses to the RUL 
ECT? A long duration of a current depressive episode (Black et al., 1993; Prudic et al., 
1996), and failure to respond to one or more adequate medication trials have been shown to 
predict a diminished rate of ECT response (Prudic et al., 1996). In this study, there were no 
differences between these variables in the depression groups. Furthermore, when patients 
take BZDs during a course of unilateral ECT, the maximum therapeutic response may be 
compromised (Pettinati et al., 1990). The mean dose of lorazepam (1.1 mg/d) of the patients 
(V) was at the same level as in the previous efficacy studies (1.0 mg/d, and 1.2 mg/d) 
(Sackeim et al., 2000a; Sackeim et al., 1993, respectively). In Study V, the mean dose of 
lorazepam was not different between the depression groups. Findings regarding the effects of 
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age on short-term efficacy of ECT have been somewhat inconsistent. Some studies have 
reported that advancing age can be used to predict good response to ECT (Black et al., 1993; 
Tew et al., 1999) while other studies have not found this relationship (Brodaty et al., 2000). 
Thus, the higher mean age of our Group 1 patients may have had some beneficial effect on 
their treatment outcome as compared to Group 2 patients, but on the other hand, the lower 
mean age in Group 2 may reflect a greater burden of co-morbidity leading to earlier referral 
for ECT. The patients in Group 2 had less severe depression than those in Group 1. None of 
the patients who were included in the analysis because of a mild major depression (Group 2) 
responded to the ECT treatment. This finding is in agreement with that of Hamilton and 
White (1960) and questions, in general, the usefulness of RUL ECT in patients with a major 
depression of low severity.  
 
Many of the patients in Group 2 had secondary major depression (Feighner et al., 1972; 
Spitzer et al., 1978), i.e. they had some preexisting non-affective psychiatric disorder (which 
may or may not still be present), or a serious or life-threatening medical illness, which 
precedes and parallels the symptoms of depression. Specifically, eight patients had a history 
of alcohol abuse during the previous year, six patients had a history of schizophrenia, 
schizoaffective disorder or another psychotic disorder which was not part of the mood 
disorder (four patients had psychotic disorder not otherwise specified, and two 
schizoaffective disorders), two patients had a history of a neurological illness (one patient 
had cerebellar ataxia, and the other ischemic cerebrovascular disease) and four patients had a 
history of a severe medical illness (three patients had hypertensive cardiovascular disease 
with concomitant risk factors: one had an aortic homograft, one a history of epilepsy, one a 
risk for esophageal reflux, and one patient had coronary artery disease with coronary artery 
bypass grafting). It has been shown that patients with secondary depression are less likely to 
recover from the index depressive episode (Coryell et al., 1985) and are more likely to 
receive inadequate treatment (Black et al., 1987) than patients with primary major 
depression. Moreover, patients with secondary depression have been found to have a poorer 
response to ECT treatment than patients with a primary depressive disorder (Davidsson et al., 
1980; Zorumski et al., 1986; Black et al., 1987; Black et al., 1993). Zorumski et al. (1986) 
found that patients with alcohol dependence and secondary depression had a favorable 
response to ECT. However, concurrent alcohol dependence diminishes the likelihood that 
depression will respond to treatment (Mueller et al., 1994). The subgroups in Study V were 
too small for any statistical analyses but one may conclude that the lack of ECT efficacy in 
Group 2 was due to the prevalence of secondary depression in this group especially as the 
effect of ECT was lower in Group 2 than in Group 1 also after an adjustment for initial 
differences in severity of depression and age between the two groups. This finding is in 
agreement with the suggestion that it is likely that ECT does have specific brain effects that 
affect individuals differently because their individual substrate differ (Fink, 1993a). 
 
6.10. Side effects of ECT 
None of the ECT treatments (I-V) were fatal. ECT may cause a variety of cardiovascular 
complications including cardiac arrest, arrhytmias, ischemias, hypertension, and hypotension 
(Dec et al., 1985; Prudic et al., 1987; Zielinski et al., 1993; Rice et al., 1994). One excluded 
BF ECT patient (P1, Studies II, III and IV) had a 20-s asystole despite of premedication with 
atropine. The asystole resolved spontaneously. The patient had a history of hypertension 
treated with beta blockers, and prior to ECT, she had had doxepine withdrawal for six days. 
The subconvulsive stimulus accompanied with vagal stimulation despite use of atropine and 
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use of the beta blocker may have contributed to the occurrence of asystole as suggested by 
McCall (1996). Furthermore, ventricular extrasystole was found in one RUL ECT 2.5 patient 
(IV) and high elevations of blood pressure in two patients treated with RUL ECT 5 (V). The 
ECT-induced increases in heart rate and systolic blood pressure have been found to increase 
the rate pressure product (RPP), i.e. an index of myocardial oxygen demand (Mayur et al., 
1998). Furthermore, ECT has been found to increase the QT dispersion, i.e., maximal QT 
interval minus minimal QT interval. This increased heterogeneity of ventricular 
repolarization may be associated with enhanced vulnerability to arrhythmias during ECT 
(Guler et al., 1998). In the study of Mayur et al. (1998) none of the cardiac-healthy patients 
(n = 95) had any clinically observable cardiac complications with ST level (mean dose 68 
mC) RUL ECT. The RUL ECT doses of Studies IV and V were significantly higher. 
Therefore, there is a need to further study cardiovascular side-effects induced by 
suprathreshold RUL ECT. On the other hand, the cardiovascular monitoring of the patients 
during the ECT treatments was continuous and effective. 
 
Abrams (see 1997) points out that when increasingly higher doses become routine for RUL 
ECT in order to maximise therapeutic impact, objective memory deficits may become 
manifest. Some of the RUL ECT patients with low seizure thresholds (II and III) would have 
been treated with stimulus doses more than ten times their individual ST level if the AM 
would have been used. All RUL patients with low ST levels would have received a very high 
(15x ST) RUL ECT dose if the FHDM (Abrams et al., 1991) would have been used. McCall 
et al. (2000a) have found that when the RUL ECT stimulus is dosed at approximately 8-13x 
ST level compared with dosing at 3-5x ST level, global cognitive disturbances increase more 
than the antidepressant response does. Facilities vary considerably in many aspects of ECT 
practice, often clearly departing from the standards in the field (Prudic et al., 2001). Prudic et 
al. (2001) have found that the more intensive the form of ECT used at facilities, the less 
intensive the assessment of ECT-induced cognitive side effects. Therefore, I suggest that no 
FHDM (dose ≥ 378 mC) should be used if the RUL ST level has not been estimated.  
 
The high-dose RUL ECT, despite its therapeutic advantages, did not result in greater MMSE 
impairment after ECT than the moderate dose RUL or the low-dose BF ECT (IV). BF 
stimulus has been shown to spare both verbal and nonverbal cognitive functions better than 
BT and RUL ECT treatment if the BF stimulus is dosed just above the individual ST level 
(Lawson et al., 1990). However, Study IV suggests that such a dose may have a slow 
response and therefore, higher doses may be required. Then, both profile and amount of 
cognitive side-effects may become more evident in BF ECT. 
 
The patients (I-V) had no prolonged seizures (>180 seconds) as measured either using motor 
seizure monitoring or using the automated EEG monitoring of the Thymatron ECT device. 
The lack of prolonged seizures (I-V) is in disagreement with the study of Mayur et al. (1999). 
They found that prolonged seizures using only motor seizure monitoring would have been 
missed in about 6% of patients. However, also I recommend a routine use of EEG seizure 
monitoring to detect prolonged seizures which can occur without motor manifestations but 
still can be harmful for the function of the brain. 
 
One patient (V) had to discontinue the course of ECT treatment because of a hypomanic 
switch. The low switch rate (1%) in this thesis is in agreement with that (≤ 4%) reported by 
Devanand et al. (1992). 
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One patient (V, Group 2) had to discontinue the course of ECT because of regurgitation of 
his gastric contents. This rare side-effect of ECT may predispose to aspiration pneumonia 
(see Royal College of Psychiatrists, 1995). We did not use a nasogastric tube before 
anesthesia. Thus, the beneficial effect of this proposed method can not be answered by this 
study.  
6.11. Risk and benefit analysis of ECT 
This study clearly demonstrates that both cardiovascular and cognitive side-effects must be 
included in the risk and benefit analysis of the ECT treatment. Four patients discontinued 
their ECT treatments because of cardiovascular complications. Furthermore, the possibility 
for simultaneous worsening in global cognitive status and nonresponse to RUL ECT 
treatment was found to be significantly high for depressive patients with comorbid conditions 
or with low severity of depression. In the clinical practice, comorbidity is common. Until 
there are more studies on depressive patients with co-morbidity or low symptom severity, the 
risk/benefit ratio has to be assessed individually in different subgroups of patients with major 
depression. 
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7. CONCLUSIONS 
 
Study I. The findings support the possibility that an efficient ECT treatment regardless of 
ECT stimulus placement and stimulus dose induces a relative accentuation of frontal MEG 
slow-wave activity. 
 
Study II. In contrast to RUL ECT, the seizure duration does not show any association with 
the threshold level BF ECT stimulus. The lack of an inverse relationship for BF ECT may be 
due to our overestimation of the first stimulus level and also to the use of too large 
increments between stimuli. Thus, it can not be excluded that lower BF doses might induce 
longer seizures accompanied with impaired efficacy.  
 
Study III. Patients with different seizure thresholds would be treated differently if the 
predetermined dose is used both for RUL ECT and BF ECT groups. Especially, patients with 
low seizure thresholds are in danger of being treated with supra-high stimulus doses. The 
safety of such doses is questionable. We recommend the use of the dose titration method, i.e. 
measurement of the individual seizure threshold in the first ECT treatment, followed by an 
ECT treatment relative to it. Only the dose titration method allows us to standardize the ECT 
stimulus dose relative to the initial seizure threshold level.  
 
Study IV. High-dose (5x ST) RUL ECT has a faster antidepressant effect than low-dose 
(1.0x ST) BF ECT. BF placement has to be considered as experimental, and it can not be 
recommended for routine clinical use until further trials are completed. The cognitive 
risk/benefit ratio using different BF stimulus doses should be further studied with more 
sensitive neuropsychological methods. 
 
Study V. The good response to RUL ECT of the patient group with major depression without 
co-morbidity was not found in a heterogeneous co-morbid patient group. Most of the patients 
in this group had secondary major depression. In addition, patients with a low severity of 
major depression have a high risk/benefit ratio and this makes the RUL ECT treatment 
unjustified for them. More research is needed to clarify the response to ECT treatment in 
different subgroups of patients with major depressive episodes. 
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